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CHAPTER 1: INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of late life dementia and 
represents the fourth leading cause of death in the developed world (Soto, 1999). In 
2006, the worldwide prevalence of AD was 26.6 million (Brookmeyer et al., 2007). In 
Malaysia, approximately 20,000 Malaysians are currently diagnosed with the illness. 
AD prevalence is approximately 1 % between 65 and 69 years and is higher than 50 % 
in individuals over 95 years (Racchi et al., 2008). 
 
AD is characterized by severe memory loss and cognitive impairment, with the 
degenerative loss of basal forebrain cholinergic neurons (Fodale et al., 2006) and 
extensive reduction of cholinergic acetyltransferase (ChAT) activity in the cerebral 
cortex hippocampus (Davies and Maloney, 1976). Besides the damage in the 
cholinergic system, the formation and growth of brain amyloid lesions, the senile 
plaques, is also widely believed to be a crucial event in the pathogenesis of AD 
(Schaeffer et al., 2011). Current therapies include the use of acetylcholine (ACh) 
precursors, muscarinic agonists and acetylcholinesterase (AChE) inhibitors (Amenta et 
al., 2001). 
 
 The principal role of AChE is the termination of nerve impulse transmission at 
the cholinergic synapses by rapid hydrolysis of ACh. Hence AChE inhibitors can be 
used to increase the amount of acetylcholine present in the synapses between 
cholinergic neurons in order to improve cholinergic function in AD patients (Jung and 
Park, 2007). Although the AChE inhibitors donepezil, galantamine, rivastigmine and 
tacrine have been approved by the Food and Drug Administration (FDA) in the United 
States, these drugs have only modest effects on clinical benefit and do not prevent 
disease progression (Vardy et al., 2005). 
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Reports that the ability of AChE to promote amyloid formation is inhibited by 
propidium and decamethonium, point to involvement of the peripheral anionic binding 
site in the interaction of the enzyme with amyloid beta (Aβ) peptide (Inestrosa et al., 
1996). Furthermore, several AChE inhibitors have been found to activate the non-
amyloidogenic pathway and thus to reduce Aβ production (Racchi et al., 2004). They 
affect the expression and/or the metabolic processing of amyloid precursor protein 
(APP) essential for amyloid beta generation. Recent studies also indicate that AChE 
induces the aggregation of prion protein with a similar dependence on the peripheral 
anionic site (PAS) (Inestrosa et al., 2008). 
 
Hence suitably-designed AChE inhibitors have the potential to become drug 
candidates which are capable of not only reducing the symptoms of AD, but also 
preventing disease progression. 
 
AIMS OF STUDY 
           Most studies that have been carried out on AChE focus on the catalytic site of the 
enzyme. In this study, in addition to the catalytic site (CAS), the PAS will also be 
included in order to identify novel anticholinesterase compounds which are not only 
effective in reducing the symptoms of AD, but also preventing disease progression. 
 
           In the current study, virtual screening on commercially available compound 
libraries was performed to determine the binding mode of these inhibitors to the AChE. 
The AChE inhibitory activity of each compound was evaluated. Those compounds 
which showed promising activity were further evaluated for β-amyloid aggregation 
inhibitory activity. 
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The specific objectives of this study are as follows:- 
 
1. To perform virtual screening on commercially available compound libraries to 
predict their anticholinesterase activity. 
 
2. To optimise assays to determine inhibition of AChE and Aβ peptide 
aggregation. 
 
3. To assay selected compounds for inhibition of AChE and Aβ peptide 
aggregation. 
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CHAPTER 2: LITERATURE REVIEW  
2.1 THERAPEUTIC STRATEGY IN ALZHEIMER’S DISEASE TREATMENT                          
There are two main approaches for treatment of Alzheimer’s disease (AD):- 
(a) Cholinergic hypothesis and enhancement of cholinergic function 
The findings that AD is associated with impairment in the cholinergic system 
led to the cholinergic hypothesis, which relates the neuronal degeneration with the loss 
of cholinergic neurotransmission (Terry and Buccafusco, 2003). Therefore, increasing 
cholinergic transmission may enhance cognitive function (Figure 2.1) (Alhomida et al., 
2000). Cholinergic deficits in AD patient can be enhanced through various mechanisms of 
action in different parts of the cholinergic neurotransmission system.  
 
 Choline precursors, such as phosphatidylcholine, aimed at increasing the 
bioavailability of choline, ACh (acetylcholine) releasers, which facilitate the release of 
ACh from presynaptic end terminals, nicotinic agonists which enhance ACh release and 
acetylcholinesterase (AChE) inhibitors can be used to help overcome cholinergic deficits 
in AD patients. So far, the use of AChE inhibitors seems to be the most effective method 
for reducing the symptoms of the disease. Their mode of action is to block the AChE 
enzyme thereby stimulating cholinergic activity and enhancing cognitive function 
(Racchi et al., 2004). 
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Figure 2.1: The mechanism of cholinergic neurotransmission. After signaling, 
acetylcholine is released from receptors and broken down by acetylcholinesterase to be 
recycled in a continuous process. Adapted from http://www.vrp.com/why-vrp on 28th 
April, 2012) 
 
(b) Reduction or prevention of deposition of amyloid peptides 
Amyloid beta (Aβ) peptide is a main component of senile plaques and fibrillary 
tangles that constitute one of the neurohistopathological features of AD. The Aβ peptide 
(39–43 amino acids) is generated by the proteolytic processing of the amyloid precursor 
protein (APP) (Inestrosa et al., 1996). APP is processed by one of two pathways: the 
amyloidogenic pathway leading to the production of Aβ (involving β and γ secretase) 
and the non-amyloidogenic pathway (involving α and γ secretase) (Vardy et al., 2005). 
The non-amyloidogenic pathway precludes the accumulation of Aβ (Tang, 2005) 
(Figure 2.2).  
 
Incorporation of AChE into Alzheimer’s amyloid aggregates results in the 
formation of stable complexes that change the biochemical and pharmacological 
properties of the enzyme and increase the neurotoxicity of Aβ fibrils (Inestrosa et al., 
1996). Association of AChE with Aβ and the formation of amyloid fibrils can be 
inhibited by peripheral anionic site (PAS) ligands such as propidium (Inestrosa et al., 
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1996). Reduction of Aβ production, either through inhibition of β and γ secretase or 
through activation of α secretase, is also a potential therapeutic approach for AD (Vardy 
et al., 2005). 
 
 
Figure 2.2: The amyloid cascade hypothesis. The APP is processed by β and γ 
secretases via the amyloidogenic pathway to yield a variety of toxic Aβ-containing 
species, ultimately resulting in neuronal cell death. These amyloidogenic species can be 
degraded by a number of catabolic proteases such as neprilysin, IDE and plasmin, 
thereby clearing Aβ and preventing cell death. The non-amyloidogenic pathway results 
from α secretase cleavage within the Aβ sequence of APP (adapted from Jacobsen et al., 
2005).     
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2.2 ACETYLCHOLINESTERASE INHIBITORS 
Several AChE inhibitors are available for the treatment of mild to moderate AD 
namely donepezil, galantamine, rivastigmine and tacrine (Figure 2.3). Tacrine was the 
first compound to come into clinical use, but it has now been replaced by the second 
generation inhibitors which are safer and have longer lasting effects. Rivastigmine is 
irreversible inhibitor whereas donepezil, galantamine and tacrine are reversible 
inhibitors. An inhibitor such as donepezil may bind to both the catalytic site (CAS) and 
PAS while others such as tacrine have higher affinity for the CAS compared to the PAS. 
 
The important binding groups for an AChE inhibitor appear to be a positively 
charged nitrogen and a hydrogen-bonding group, separated by a lipophilic region. Since 
a positively charged nitrogen is common in many alkaloids at body pH, it is not 
surprising that many of the most powerful AChE inhibitors come from this class of 
compounds (Houghton and Howes, 2005).  
 
 (-)-Huperzine A is a natural compound (alkaloid) first isolated from Chinese 
medicine Huperzia serrata in 1986 (Filho et al., 2006). The protopine and palmatine 
from the aerial parts of Corydalis speciosa (Kim et al., 2004) are also alkaloids that 
have been isolated and were reported to inhibit AChE activity. 
 
 However, a number of other natural products which do not contain any nitrogen, 
have been found to be AChE inhibitors such as the triterpene ursolic acid (Chung et al., 
2001), the flavonoid linarin (Fan et al., 2008), the sterol haloxysterol B (Ahmed et al., 
2006) and the coumarin decursin (Kang et al., 2003). Non-nitrogen containing 
compounds may provide information on other features which are necessary for the 
activity. 
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2.3 VARIOUS ROLES OF ACETYLCHOLINESTERASE INHIBITORS 
AChE interacts with the Aβ peptide and promotes amyloid fibrils formation by a 
hydrophobic environment close to the PAS of the enzyme (De Ferrari et al., 2001). This 
can be inhibited by PAS ligands such as propidium (Inestrosa et al., 1996). However 
knowledge of the relationship between AChE activity and Aβ toxicity is still limited. 
 
A number of studies on designing and synthesizing new dual acting compounds 
have been carried out. For example, it has been reported that piperidine derivaties and 
donepezil- tacrine hybrid related derivatives have dual inhibitory potency against AChE 
and Aβ1-42 peptide aggregation that could bind simultaneously to the PAS and CAS 
binding site of the enzyme (Kwon et al., 2007; Alonso et al., 2005).                        
 
There is some evidence that some molecules may protect neurons from 
neurodegenerative insults including deposition of Aβ. Donepezil has been found to 
exert a neuroprotective effect by reducing the amount of the toxic form of Aβ in septal 
neuron cultures, independent of inhibition of AChE activity (Kimura et al., 2005). 
Likewise another compound (-)-huperzine A (Figure 2.3) has been demonstrated to 
protect neuronal and glial cells against cytotoxicity of Aβ (Zhang et al., 2002). 
 
A remarkable inhibition of MSA (maximum size of aggregation) was obtained 
with propidium iodide, suggesting that AChE triggers PrP 106–126 and Aβ aggregation 
through a similar mechanism. Huprines (AChE inhibitor) also significantly decreased 
MSA induced by AChE as well (Pera et al., 2006), suggesting the PAS of the AChE is 
involved both in the Aβ and PrP pro-aggregating effect. 
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Pakaski et al. (2000) reported that metrifonate (AChE inhibitor) can increase the 
cell-associated APP level in a basal forebrain neuronal culture and also elevate the 
amount of APP secreted into medium thus suggesting that AChE inhibitors modulate 
APP processing via a stimulatory effect on Protein kinase C (PKC). It has also been 
stated that the effects of Huperzine A on the elevation of acetylcholine levels might 
contribute to an increase in secreted amyloid precursor protein-α (sAPPα) release 
because it might stimulate the muscarinic acetylcholine receptors M1 and M3 mediating 
the PKC pathway (Yan et al., 2007). 
 
2.4 MOLECULAR MODELING STUDIES ON ACETYLCHOLINESTERASE 
           The X-ray crystallographic structure of the Torpedo californica 
acetylcholinesterase (TcAChE) (Protein Data Bank (PDB) code: 1acj) (Sussman et al., 
1991) (Figures 2.4 & 2.5) an enzyme monomer with 537 amino acids, shows that the 
CAS consists of the Ser200-His440-Glu327 triad. It is located near the bottom of a 
deep, narrow cavity, named the ‘active-site gorge’, lined by 14 aromatic residues. Of 
these 14 residues, Trp84 and Phe330 are involved in the so called ‘anionic’ subsite of 
the CAS, making π-cation interactions with the quaternary amino group of the substrate 
(Harel et al., 1993). Trp279 and Tyr70 contribute to the PAS at the mouth of the gorge 
(Eichler et al., 1994) and Trp233, Phe288 and Phe290 contribute to the acyl pocket 
(Harel et al., 1996). The structure of recombinant monomeric mouse 
acetylcholinesterase (mAChE) in complex with fasciculin-II (FAS-II) (PDB code: 
1mah), provided the first mammalian cholinesterase template. A close structural 
similarity is observed between mAChE and TcAChE (Bourne et al., 1995). 
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Figure 2.4: Ribbon diagram of TcAChE complex with ACh, displayed as a ball-and-
stick model, docked in the active site (adapted from Silman and Sussman, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Schematic cross-sections through the active-site gorge of TcAChE, showing 
the principal residues involved in the CAS and PAS and the catalytic triad (adapted 
from Silman and Sussman, 2008).  
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  The amino acid sequence of human acetylcholinesterase (hAChE) has been 
determined (Soreq et al., 1990) and shown to have high homology with the TcAChE. In 
particular, the residues constituting the surface of the ligand-binding pocket are 
identical except for Phe330, which is replaced by Tyr337 in the hAChE (Figure 2.6) 
(Belluti et al., 2009; Yamamoto et al., 1994). The x-ray crystallographic structure of 
hAChE in complex with FAS-II (PDB code: 1b41) (Kryger et al., 2000) revealed 
corresponding residues in hAChE and TcAChE (see figure 2.7 for comparison of the 
structures). Conservation of the amino-acid residues lining the active site gorge is very 
high: 26 residues are identical, two are similar, viz. Thr83(Ser81) and Tyr337(Phe330), 
and only two residues, both at the mouth of the gorge, are different in hAChE and 
mAChE versus TcAChE, viz. Thr75(Glu73) and Leu76(Gln74) (Table 2.1). In AChE 
from bovine erythrocytes, the Phe330 in TcAChE is replaced by Tyr330. 
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Table 2.1: The identity and numbering of the residues in the different species.  
Species & Residues involved Binding sites 
TcAChE mAChE HAChE 
Acyl pocket Trp233 
Phe288 
Phe290 
 
Phe295 
Phe297 
 
Phe295 
Phe297 
CAS 
 
 
 
 
Trp84 
Phe330 
Ser200 
His440 
Glu327 
Trp86 
Tyr337 
Ser203 
His447 
Glu334 
Trp86 
Tyr337 
Ser203 
His447 
Glu334 
PAS Tyr70 
Glu73 
Gln74 
Trp279 
Tyr72 
Thr75 
Leu76 
Trp286 
Tyr72 
Thr75 
Leu76 
Trp286 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Superimposition of the structures of hAChE (blue) and TcAChE (red) (Liu 
et al., 2009). 
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Figure 2.7: Docking model of a donepezil analogue with hAChE (A) and TcAChE (B) 
(Belluti et al., 2009). 
 
 The complex formed between huperzine A and single-site and double site 
mutants of recombinant hAChE (rhAChE) showed that Tyr at position 337 is essential 
for inhibition of rhAChE by huperzine A (Ashani et al., 1994). Docking studies using 
TcAChE have shown that inhibitors such as donepezil-tacrine hybrids and indole-
tacrine heterodimers also are stacked against the aromatic rings of Trp84 and Tyr330 at 
the catalytic site and Trp279 at the PAS (Alonso et al., 2005; Munoz-Ruiz et al., 2005).  
 
Comparison of the effects of ‘peripheral site’ ligands such as propidium and 
fasciculin (FAS) on TcAChE and chicken AChE has indicated that they are more 
effective inhibitors of TcAChE due to the absence of the two aromatic residues Tyr70 
and Trp279 in the chicken enzyme (Eichler et al., 1994; Harel et al., 1995). FAS 
association with several mutant forms of recombinant DNA derived AChE from mouse 
have shown that the aromatic residues Tyr72, Tyr124 and Trp286 have the most marked 
influence on FAS binding (Radic et al., 1994). 
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2.5 DOCKING 
 Docking is a process which brings two molecular structures together so that 
binding occurs. The binding site is the part of the protein where the ligand binds. The 
binding site can be identified by looking at the crystal structure of the protein bound 
with a known inhibitor. The conformation of the ligand in the binding site is called the 
binding mode. Generally, protein-ligand docking software consists of two main 
components that work together, a search algorithm and a scoring function. The search 
algorithm generates a large number of poses of a molecule in the binding site while the 
scoring function calculates a score or binding affinity for a particular pose. Scoring 
functions can be divided into forcefield-based, empirical and knowledge-based 
potentials. There are a number of docking programmes available such as AutoDock 
(Morris et al., 1998), Dock (Kuntz et al., 1982), Drawin, E-Hits, FlexX (Rarey et al., 
1996), FRED, Glide (Friesner et al., 2004), Gold (Jones et al., 1997), LigandFit, QXP, 
Slide and Surflex-Dock. 
 
2.6 VIRTUAL SCREENING 
In drug discovery, the physical screening of large libraries of chemicals against 
a biological target (high-throughput screening) is a dominant technique for the 
identification of new lead compounds. An alternative approach, known as virtual 
screening is to computationally screen large libraries of chemicals for compounds that 
complement targets of known structure, and experimentally test those that are predicted 
to bind well. This approach has been found to produce hit rates (ligands discovered per 
molecules tested) significantly greater than those obtained with high-throughput 
screening (Shoichet, 2004). 
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2.6.1 Virtual screening can be divided into two:- 
(a) Structure based virtual screening 
      Involves automated and fast docking of a large number of chemical compounds  
      against a protein-binding or active site (Reddy et al., 2007). 
 
(b) Ligand based virtual screening 
Databases of chemical structures are searched to find compounds that are similar to 
known actives (similarity searching) or posses a pharmacophore or substructure in 
common with a known active (pharmacophore substructure searching) (Reddy et al., 
2007). 
 
Docking algorithms for structure based virtual screening can be broadly classified into 
three categories (Figure 2.8):- 
(a) Searching the conformational space during docking 
(b) Searching the conformational space before docking 
(c) Incremental docking  
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Figure 2.8: Classification of various methods of structure based virtual screening 
(http://www.slideshare.net/baoilleach/proteinligand-docking). 
 
Virtual screening methods have been applied in recent years in order to find lead 
compounds for many targets such as Human Immunodeficiency Virus (HIV), AChE, 
Severe Acute Respiratory Syndrome (SARS), Cystein protease and Mycobacterium 
tuberculosis (MTB). In particular, there have been several successful cases reported for 
the synthesis of potential AChE inhibitors by the virtual screening procedure.  
 
Taking AChE as target, a structure based pharmacophore model was generated 
and screening was conducted over 110 000 natural products which resulted in 
identification of effective AChE inhibitors, scopoletin and scopolin (Rollinger et al., 
2004). In another study, virtual screening of about 160 000 commercially available 
compounds against the X-ray crystallographic structure of AChE was performed by 
Mizutani & Itai (2004) by employing a new method called ADAM & EVE. This study 
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found 13 compounds which had IC50 values between 0.5 and 10 µM and almost all their 
core structures are very different from those of known inhibitors. 
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CHAPTER 3: ACETYLCHOLINESTERASE MODEL BUILDING, SELECTION 
OF PROTEIN CRYSTAL STRUCTURES AND VIRTUAL SCREENING OF 
UNKNOWN LIGANDS 
 
3.1 INTRODUCTION 
 The Brookhaven Protein Data Bank (PDB) is a repository of protein crystal 
structures, often in complexes with inhibitors. The PDB contains several crystal 
structures of acetylcholinesterase (AChE) such as human acetylcholinesterase (hAChE), 
Torpedo californica acetylcholinesterase (TcAChE), mouse acetylcholinesterase 
(mAChE) and bovine erythrocytes acetylcholinesterase.  
 
 In the current study, several crystal structures of AChE were extracted from the 
PDB and docked with known ligands to find the most suitable protein structure for 
virtual screening. The selected protein was then docked with large libraries of 
commercially available ligands using computational procedures in order to identify 
potential anticholinesterase compounds. 
 
3.2 MATERIALS AND METHODS 
Work station, molecular modeling software. 
 
3.2.1 Model building and model selection of protein crystal structures 
3.2.1.1 Preparation of protein file 
 
           The AChE crystal structures, hAChE in complex with fasciculin II (2.76 Ǻ) 
(PDB ID: 1b41), TcAChE in complex with aricept (2.50 Ǻ) (PDB ID: 1eve), mAChE in 
complex with gallamine (2.20 A°) (PDB ID: 1n5m), mAChE in complex with decidium 
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(2.35 A°) (PDB ID: 1j07), mAChE in complex with succinylcholine (2.05 A°) (PDB 
ID: 2ha2) and mAChE in complex with propidium (2.25 A°) (PDB ID: 1n5r) were 
extracted from the PDB as pdb files. The heteroatoms and water molecules were 
removed using Discovery Studio Visualizer 3.1 (Accelrys, Inc, Sandiego, CA, USA). 
Hydrogen atoms were added and double coordinates were corrected using Hyper chem 
Pro 6.0 software. Some modifications were carried out on TcAChE crystal structure, 
PDB ID: 1eve to better reflect the binding site sequence in hAChE, resulting in five 
different protein files as outlined below:- 
 
(a) Without any replacement of residues or energy minimization 
 
(b) With residue Phe330 replaced by Tyr  
 
(c) With residue Phe330 replaced by Tyr followed by energy minimization using 
Swiss PDB Viewer (SPBV 4.01) 
 
(d) With residue Phe330 replaced by Tyr, Ser81 replaced by Thr, Glu73 replaced by 
Thr and Gln74 replaced by Leu 
 
(e) With residue Phe330 replaced by Tyr, Ser81 replaced by Thr, Glu73 replaced by 
Thr and Gln74 replaced by Leu followed by energy minimization using Swiss 
PDB Viewer (SPBV 4.01) 
 
 Then, again hydrogen atoms were added and non polar hydrogens were merged 
using AutoDock Tools 1.5.2 software. The protein files were checked for any missing 
atoms and atoms were added as necessary. Kollman charges were also added and the 
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values were recorded. Finally, AutoDock 4 type atoms were assigned to the proteins 
and the files were saved in pdbqt format. 
 
3.2.1.2 Preparation of standard ligand file 
  Three dimensional structural models of 19 well known AChE inhibitors (Figure 
3.1) were downloaded in mol2 format from Drug bank (http://drugbank.ca/) and Pub 
chem (http://www.ncbi.nlm.nih.gov/pccompound). These compounds were prepared in 
protonated form where appropriate for physiological pH. Then, the compounds were 
minimized through the Hyper chem Pro 6.0 software to the lowest energy. Ligand files 
were then saved in pdbqt format. 
 
3.2.1.3 Preparation of grid parameter file (gpf) 
           The protein file and the selected ligand file were opened together in AutoDock 
Tools 1.5.2 software. A grid box was created by adjusting the defaults value to cover 
the entire protein. The spacing was set to a default value of 0.375, and the file extension 
was set as “.gpf”. Gpf files were created for other ligands as well. The same process 
was repeated for all protein structures. 
 
3.2.1.4 Preparation of the docking parameter file (dpf) 
           The protein file and the selected ligand file were opened together in AutoDock 
Tools 1.5.2 software. The docking parameters were set as number of ga runs = 100, 
number of individuals in population = 150 and maximum number of energy 
minimization (medium) = 2500000. Cluster tolerance (rmstol) value was set as 2.0 and 
Lamarckian genetic algorithm was used. The file extension was set as “.dpf”. Dpf files 
were created for other ligands as well. The same process was repeated for all protein 
structures. 
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3.2.1.5 Running autodock 
Running autodock using the Linux operating system requires a protein file, a 
ligand file, a gpf and a dpf file. Autogrid was run using the command line, autogrid4 –p 
filename.gpf –l filename.glg &. Autogrid was followed by autodock using the command 
line autodock4 –p filename.dpf –l filename.dlg &. The process was repeated for each 
protein and each ligand. 
 
3.2.1.6 Docking analysis 
Ligand - protein interactions were analyzed using Viewer Lite, Discovery Studio 
Visualizer 3.1 (Accelrys, Inc, Sandiego, CA, USA) and Ligplot 4.4.2 softwares.  
Ligands which showed high affinity for the enzyme and the most suitable protein for 
virtual screening were identified.  
 
3.2.2 Virtual screening of unknown ligands 
3.2.2.1 Preparation of protein file 
The AChE crystal structure (PDB code: 1b41) was chosen for virtual screening. 
 
3.2.2.2 Preparation of ligand file 
The ‘ZINC’ database (http://zinc.docking.org/search/) was explored using 
decamethonium, MF268 and propidium as the backbone structure for the ligands to find 
commercially available ligands. About 830 unknown ligands in mol2 format were 
downloaded from ZINC database. The mol2 file was split and each ligand was named 
according to its ZINC id. These ligands were prepared in protonated form where 
appropriate for physiological pH. 
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3.2.2.3 Virtual screening 
The number of evaluations for the virtual screening was set to 1750000, the 
population size was set to 150, the number of runs was set to 20, the spacing was set to 
0.375 and the rmstol value was set to 2.0. 
 
3.2.2.4 Docking analysis 
The Autodock log file with the extention .dlg file for each ligand consisting of a 
clustering histogram where details such as cluster rank, lowest binding energy and 
number of cluster was obtained. A pdb file was created for each ligand from the dlg file. 
These pdb files and the protein file were opened in DS Visualizer software to analyse the 
ligand - protein interactions. The binding site of the ligand in the protein and the lowest 
binding energy were recorded. The residues involved in hydrogen bonding, Van der 
waals interactions and pi-pi interactions between the ligand and protein were recorded. 
Hydrophobic interactions were analyzed using Ligplot 4.4.2 software. Ligands which 
show high affinity for the enzyme were identified.  
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Figure 3.1: Structures of known AChE ligands. 
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Figure 3.1: Structures of known AChE ligands (continued). 
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3.3 RESULTS AND DISCUSSION 
The protein crystal structures for model selection were chosen based on the 
resolution of the crystal structures. Ten crystal structures were investigated (Tables 
3.1–3.3, Appendices 1–27) with 19 known ligands (Figure 3.1), comprising 7 PAS 
binding ligands, 9 CAS binding ligands and 3 both PAS and CAS binding ligands. The 
sequence identity between hAChE and mAChE is about 87 % and between hAChE and 
TcAChE is about 53 % (Kryger et al., 2000). Therefore, the docking results were 
compared to mouse and TcAChE in complex with ligand found in PDB.  
 
The overall blind docking result (Table 3.4) indicated that 6 crystal structures 
(hAChE in complex with fasciculin II (2.76 Ǻ) (PDB ID: 1b41), mAChE in complex 
with gallamine (2.20 A°) (PDB ID: 1n5m), mAChE in complex with decidium (2.35 
A°) (PDB ID: 1j07), and modified models of TcAChE in complex with aricept (2.50 Ǻ) 
(PDB ID: 1eve) (b)–(d) (see section 3.2.1.1) [(except (e) which was compatible with 
PAS and both site (PAS & CAS) binders)] were compatible with PAS binding ligands.  
 
mAChE in complex with succinylcholine (2.05 A°) (PDB ID: 2ha2) and 
mAChE in complex with propidium (2.25 A°) (PDB ID: 1n5r) were found to be 
compatible towards PAS and both site (PAS & CAS) binding ligands. TcAChE in 
complex with aricept (2.50 Ǻ) (PDB ID: 1eve) was compatible towards PAS, CAS and 
both site binding ligands (Table 3.4). The ligplot analysis (Appendices 28–30) shows 
in detail the residues involved in hydrogen bonding and hydroph 
obic interactions between the proteins and ligands.  
 
The current study aimed at finding PAS binding ligands in addition to CAS 
binding ligands. Since the crystal structure of hAChE in complex with fasciculin II 
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(2.76 Ǻ) (PDB ID: 1b41) was compatible with PAS binding ligands and the only crystal 
structure that available in PDB for hAChE, this crystal structure was chosen for the 
virtual screening studies. Figure 3.2 shows the structures of top 21 compounds 
identified from virtual screening. 
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Figure 3.2: Structures of the top ligands identified from virtual screening for AChE 
binding activity. 
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Figure 3.2: Structures of the top ligands identified from virtual screening for AChE 
binding activity (continued). 
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Figure 3.2: Structures of the top ligands identified from virtual screening for AChE 
binding activity (continued). 
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Figure 3.2: Structures of the top ligands identified from virtual screening for AChE 
binding activity (continued). 
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Table 3.1: Results from the docking of standard ligands with a structure derived from 
the crystal structure of human AChE in complex with fasciculin II (2.76 Ǻ) (PDB ID: 
1b41) (arranged according to lowest binding energy).  
 
Ligand Cluster 
rank 
Lowest  
binding  
energy  
(kcal/mol) 
No. in  
cluster 
Inhibition  
constant, Ki  
(µM) 
(-)- Huprine x 1 -7.27 7 4.70  
Huperzine B 1 -7.16 18 5.67  
Huperzine A 1 -7.13 16 5.90  
(-)-Galanthamine 1 -7.09 33 6.34  
Δ9-THC 1 -6.88 13 9.05  
(-)- Huprine x 2 -6.69 22 12.56  
Huperzine A 2 -6.53 52 16.23  
Huperzine B 2 -6.47 67 18.18  
Tacrine  1 -6.40 20 20.51  
D-Tubocurarine  1 -6.01 3 39.39  
Donepezil  1 -5.89 5 48.16  
Tacrine  5 -5.86 35 51.07  
MPTP 1 -5.58 33 81.25  
Propidium 1 -5.48 3 95.81  
Decidium  1 -5.39 1 111.35  
BW284C5 1 -5.33 2 124.52  
D-Tubocurarine  5 -5.32 8 126.71  
MF268  1 -4.98 6 225.52  
Edrophonium 1 -4.68 19 368.69  
Edrophonium 2 -4.33 29 675.07  
Acetylthiocholine 1 -3.77 33 1740.00 
Acetylcholine 1 -3.76 36 1740.00  
Decamethonium 1 -3.54 2 2540.00  
Decamethonium 2 -3.39 14 3290.00  
Ambenonium 1 -2.70 1 10550.00  
Gallamine 1 +0.38 1 - 
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Table 3.2: Results from the docking of standard ligands with a structure derived from 
the crystal structure of human AChE in complex with fasciculin II (2.76 Ǻ) (PDB ID: 
1b41) (arranged according to highest number in cluster). 
 
Ligand Cluster  
rank 
Lowest  
binding  
energy 
(kcal/mol) 
No. in  
cluster 
Inhibition  
constant, Ki  
(µM) 
Huperzine B 2 -6.47 67 18.18  
Huperzine A 2 -6.53 52 16.23  
Acetylcholine 1 -3.76 36 1740.00  
Tacrine  5 -5.86 35 51.07  
Acetylthiocholine 1 -3.77 33 1740.00 
(-)-Galanthamine 1 -7.09 33 6.34  
MPTP 1 -5.58 33 81.25  
Edrophonium 2 -4.33 29 675.07  
(-)- Huprine x 2 -6.69 22 12.56  
Tacrine  1 -6.40 20 20.51  
Edrophonium 1 -4.68 19 368.69  
Huperzine B 1 -7.16 18 5.67   
Huperzine A 1 -7.13 16 5.90  
Decamethonium 2 -3.39 14 3290   
Δ9-THC 1 -6.88 13 9.05  
D-Tubocurarine  5 -5.32 8 126.71  
(-)- Huprine x 1 -7.27 7 4.70  
MF268  1 -4.98 6 225.52  
Donepezil  1 -5.89 5 48.16  
Propidium 1 -5.48 3 95.81  
D-Tubocurarine  1 -6.01 3 39.39  
BW284C51 1 -5.33 2 124.52  
Decamethonium 1 -3.54 2 2540.00  
Ambenonium 1 -2.70 1  10550.00 
Decidium  1 -5.39 1 111.35  
Gallamine 1 +0.38 1 - 
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Table 3.3: Results from the docking of standard ligands with a structure derived from the crystal structure of human AChE in 
complex with fasciculin II (2.76 Ǻ) (PDB ID: 1b41). (PRINT FRM PAGE ADJUS) 
 
LIGAND 
ACL 
(CAS) 
ACLTHIO 
(CAS / PAS ) 
AMB 
(PAS) 
BW284C51 
(BTH) 
DECA 
(BTH) 
DECI 
(PAS) 
DONE 
(BTH) 
EDR 
(CAS) 
GALLMN 
(PAS) 
(-)-GLNTM 
(CAS) 
C 
R 
LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS 
1 -3.76 
(36) 
PAS -3.77 
(33) 
PAS -2.70 
(1) 
PAS -5.33 
(2) 
PAS -3.54 
(2) 
BTH -5.39 
(1) 
PAS -5.89 
(5) 
PAS -4.68 
(19) 
PAS +0.38 
(1) 
PAS -7.09 
(33) 
PAS 
2 -3.39 
(19) 
PAS -3.45 
(15) 
PAS -0.88 
(1) 
PAS -5.06 
(3) 
PAS -3.39 
(14) 
PAS -4.93 
(1) 
PAS -5.55 
(1) 
PAS -4.33 
(29) 
PAS +0.49 
(1) 
PAS -6.49 
(8) 
PAS 
3 -2.96 
(4) 
O -3.40 
(2) 
MDL -0.67 
(1) 
O -4.86 
(1) 
PAS -3.20 
(2) 
BTH -4.72 
(2) 
PAS -5.27 
(5) 
PAS -4.12 
(11) 
O +0.55 
(2) 
PAS -6.13 
(2) 
CAS 
4 -2.87 
(1) 
O -3.37 
(13) 
PAS -0.51 
(1) 
O -4.86 
(1) 
PAS -3.07 
(8) 
PAS -4.58 
(1) 
PAS -5.00 
(1) 
PAS -4.00 
(4) 
PAS +0.78 
(1) 
PAS -5.89 
(1) 
CAS 
5 -2.84 
(2) 
O -3.19 
(7) 
O -0.51 
(1) 
O -4.75 
(1) 
PAS -2.96 
(7) 
PAS -4.50 
(1) 
PAS -4.90 
(2) 
PAS -4.00 
(3) 
PAS +0.98 
(1) 
PAS -5.11 
(2) 
O 
6 -2.76 
(7) 
O -3.15 
(5) 
O -0.31 
(1) 
PAS -4.18 
(1) 
BTH -2.87 
(3) 
O -4.49 
(1) 
PAS -4.86 
(1) 
O -3.96 
(4) 
CAS +0.99 
(1) 
O -4.95 
(11) 
O 
7 -2.76 
(8) 
O -3.00 
(1) 
O -0.07 
(1) 
O -3.81 
(2) 
O -2.70 
(3) 
O -4.41 
(2) 
PAS -4.83 
(2) 
PAS -3.92 
(7) 
PAS +1.00 
(2) 
PAS -4.86 
(1) 
O 
8 -2.74 
(3) 
O -2.93 
(2) 
O -0.01 
(1) 
PAS -3.66 
(1) 
O -2.58 
(4) 
PAS -4.30 
(1) 
PAS -4.82 
(1) 
PAS -3.88 
(1) 
PAS +1.04 
(1) 
O -4.83 
(2) 
O 
9 -2.68 
(2) 
CAS -2.86 
(1) 
CAS +0.00 
(1) 
O -3.63 
(4) 
O -2.47 
(5) 
PAS -4.29 
(1) 
PAS -4.80 
(1) 
PAS -3.80 
(3) 
O +1.08 
(1) 
PAS -4.79 
(2) 
O 
10 -2.59 
(2) 
O -2.81 
(1) 
O +0.12 
(1) 
O -3.56 
(1) 
PAS -2.06 
(1) 
O -3.78 
(1) 
PAS -4.80 
(1) 
PAS -3.72 
(1) 
C +1.11 
(2) 
O -4.77 
(1) 
O 
11–100  O  CAS/
O 
 PAS/
O 
 PAS/
O 
 PAS/
O 
 PAS/
O 
 PAS/
O 
 CAS/
O 
 PAS/
O 
 O 
(*/100) 
√/ X 
 (2) 
X 
 (67) 
√ 
 (9) 
√ 
 (1) 
X 
 (4) 
√ 
 (25) 
√ 
 (-) 
X 
 (10) 
X 
 (24) 
√ 
 (3) 
X 
 
CR = Cluster rank, PAS = Peripheral anionic site, CAS = Catalytic site, LBE = Lowest binding energy (kcal/mol), O = Bind to other site compared to PAS and CAS, MDL = Bind in between PAS 
and CAS, BTH = Bind at PAS and CAS, X = The binding location is incorrect according to literature, √ = The binding location is correct according to literature, (*/100) = Total conformation (the 
binding location is correct according to the literature) over 100 runs. 
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LIGAND 
HUPA 
(CAS) 
HUPB 
(CAS) 
(-)-HUP X 
(CAS) 
MF268 
(PAS) 
MPTP 
(CAS) 
PROP 
(PAS) 
TAC 
(CAS) 
Δ9-THC 
(PAS) 
TUBO 
(PAS) 
 
C 
R 
LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS LBE BS   
1 -7.13 
(16) 
CAS -7.16 
(18) 
CAS -7.27 
(7) 
PAS -4.98 
(6) 
PAS -5.58 
(33) 
PAS -5.48 
(3) 
PAS -6.40 
(20) 
CAS -6.88 
(13) 
PAS -6.01 
(3) 
PAS   
2 -6.53 
(52) 
PAS -6.47 
(67) 
PAS -6.69 
(22) 
PAS -4.53 
(6) 
PAS -5.37 
(21) 
PAS -5.48 
(1) 
PAS -6.25 
(12) 
PAS -6.44 
(4) 
PAS -5.36 
(7) 
PAS   
3 -6.51 
(2) 
CAS -5.81 
(2) 
O -6.65 
(9) 
PAS -4.26 
(1) 
PAS -5.36 
(1) 
MDL -5.36 
(4) 
PAS -6.14 
(1) 
CAS -6.34 
(3) 
PAS -5.35 
(3) 
PAS   
4 -5.49 
(3) 
PAS -5.59 
(1) 
O -6.41 
(4) 
PAS -4.16 
(3) 
PAS -5.34 
(9) 
PAS -5.09 
(2) 
PAS -6.03 
(6) 
O -5.94 
(1) 
PAS -5.32 
(3) 
PAS   
5 -5.29 
(3) 
O -5.21 
(4) 
O -6.36 
(2) 
PAS -4.15 
(1) 
MDL -5.30 
(8) 
PAS -4.73 
(3) 
PAS -5.86 
(35) 
PAS -5.83 
(1) 
PAS -5.32 
(8) 
PAS   
6 -5.24 
(3) 
O -5.17 
(2) 
O -6.36 
(18) 
O -4.11 
(4) 
PAS -5.07 
(2) 
CAS -4.59 
(2) 
PAS -5.78 
(7) 
PAS -5.72 
(1) 
PAS -5.23 
(2) 
PAS   
7 -5.20 
(1) 
O -4.98 
(1) 
O -5.29 
(1) 
O -3.99 
(2) 
PAS -4.93 
(2) 
PAS -4.57 
(1) 
O -5.69 
(5) 
PAS -5.31 
(1) 
PAS -5.19 
(2) 
PAS   
8 -4.70 
(1) 
O -4.52 
(1) 
O -5.20 
(1) 
O -3.77 
(1) 
PAS -4.90 
(2) 
CAS -4.57 
(2) 
PAS -5.06 
(4) 
O -5.17 
(1) 
O -5.04 
(2) 
O   
9 -4.65 
(3) 
O -4.49 
(1) 
O -5.01 
(7) 
O -3.76 
(1) 
PAS -4.21 
(1) 
O -4.51 
(1) 
PAS -5.01 
(1) 
O -5.04 
(2) 
O -5.03 
(1) 
PAS   
10 -4.64 
(1) 
O -4.36 
(2) 
O -4.99 
(1) 
O -3.70 
(1) 
PAS -4.14 
(3) 
O -4.24 
(6) 
O -4.96 
(3) 
O -4.80 
(2) 
O -4.87 
(1) 
PAS   
11–100  O  O  O  PAS/
O 
 O  PAS/
O 
 O  O  PAS/
O 
  
(*/100) 
√/ X  
 (18) 
√ 
 (18) 
√ 
 (-) 
X 
 (45) 
√ 
 (4) 
X 
 (22) 
√ 
 (21) 
√ 
 (24) 
√ 
 (36) 
√ 
  
 
CR = Cluster rank, PAS = Peripheral anionic site, CAS = Catalytic site, LBE = Lowest binding energy (kcal/mol), O = Bind to other site compared to PAS and CAS, MDL = Bind in between PAS 
and CAS, BTH = Bind at PAS and CAS, X = The binding location is incorrect according to literature, √ = The binding location is correct according to literature, (*/100) = Total conformation (the 
binding location is correct according to the literature) over 100 runs (continued). 
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      Table 3.4: Suitability of the crystal structures towards PAS, CAS and BTH site binders. (PRINT FROM PAGE ADJUST - ) 
Model a Model b Model c 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 11/19 
 
PAS -  7/7 
CAS -  3/9 
BTH -  1/3       
 
Conclusion :  
Good for PAS binders 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 11/19 
 
PAS -  4/7 
CAS -  5/9 
BTH -  2/3       
 
Conclusion :                
Good for PAS , CAS & BOTH SITE binders 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 11/19 
 
PAS -  6/7 
CAS -  3/9 
BTH -  1/3       
 
Conclusion :  
Good for PAS binders 
 
Model d Model e Model f 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 12/19 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 12/19 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 13/19 
 
PAS -  7/7 
CAS -  3/9 
BTH -  1/3       
 
PAS -  7/7 
CAS -  3/9 
BTH -  1/3       
 
 
PAS -  6/7 
CAS -  4/9 
BTH -  2/3       
 
Conclusion :                
Good for PAS binders 
Conclusion :  
Good for PAS binders 
Conclusion : 
Good for PAS binders 
 
CR = Cluster rank, PAS =Peripheral anionic site, CAS = Catalytic site, BTH = Bind at PAS and CAS, Model a = HAChE in complex with fasciculin II (2.76 Ǻ) (PDB ID: 1b41), Model b = TcAChE in complex 
with aricept (2.50 Ǻ) (PDB ID: 1eve) (Without any replacement of residues or energy minimization), Model c = TcAChE in complex with aricept (2.50 Ǻ) (PDB ID: 1eve) (with residue Phe330 replaced by Tyr), 
Model d = TcAChE in complex with aricept (2.50 Ǻ) (PDB ID: 1eve) (with residue Phe330 replaced by Tyr followed by energy minimization using Swiss PDB Viewer (SPBV 4.01)), Model e = TcAChE in 
complex with aricept (2.50 Ǻ) (PDB ID: 1eve) (with residue Phe330 replaced by Tyr, Ser81 replaced by Thr, Glu73 replaced by Thr and Gln74 replaced by Leu), Model f = TcAChE in complex with aricept (2.50 
Ǻ) (PDB ID: 1eve) (with residue Phe330 replaced by Tyr, Ser81 replaced by Thr, Glu73 replaced by Thr and Gln74 replaced by Leu followed by energy minimization using Swiss PDB Viewer (SPBV 4.01)). 
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Model g Model h Model i 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 6/19 
 
PAS -  5/7 
CAS -  -/9 
BTH -  -/3       
 
Conclusion :  
Good for PAS binders 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 8/19                    
 
PAS -  5/7 
CAS -  -/9 
BTH -  2/3       
 
Conclusion :  
Good for PAS and BOTH site binders 
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 7/19                   
 
PAS -  5/7 
CAS -  -/9 
BTH -  1/3       
 
Conclusion :  
Good for PAS binders 
 
Model j   
 
No. of  ligands which the binding location is correct 
according to literature at CR 1 - 9/19 
  
 
PAS-  4/7 
CAS-  1/9 
BTH-  3/3       
  
  
Conclusion :  
Good for PAS and BOTH site binders 
  
 
CR = Cluster rank, PAS =Peripheral anionic site, CAS = Catalytic site, BTH = Bind at PAS and CAS, Model g = mAChE in complex with decidium (2.35 A°) (PDB ID: 1j07), Model h = mAChE in complex 
with propidium (2.25 A°) (PDB ID: 1n5r), Model i = mAChE in complex with gallamine (2.20 A°) (PDB ID: 1n5m), Model j = mAChE in complex with succinylcholine (2.05 A°) (PDB ID: 2ha2) (Continued). 
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Table 3.5: Docking results for compounds V1-V21 identified from virtual screening. 
 
PAS = Peripheral anionic site, CAS = Catalytic site, *Standard inhibitor 
 
 
 
Docking studies Compound 
 Binding 
energy 
(kcal 
/mol) 
Binding 
site 
Ki (µM) 
 
V1 -8.72 PAS 0.40 
V2 -8.51 PAS 0.58 
V3 -8.34 PAS 0.77 
V4 -8.30 PAS 0.83 
V5 -7.92 PAS 1.56  
V6 -7.76 PAS 2.04  
V7 -7.75 PAS 2.09  
V8 -7.50 PAS 3.16  
V9 -7.35 PAS 4.08  
V10 -7.34 PAS 4.18  
V11 -7.31 PAS 4.40  
V12 -7.29 PAS 4.56 
V13 -7.25 PAS 4.86  
V14 -7.23 PAS 5.01  
V15 -7.16 PAS 5.65  
V16 -7.13 PAS 5.90  
V17 -7.09 PAS & CAS 6.40  
V18 -7.08 PAS & CAS 6.42  
V19 -7.00 PAS 7.41  
V20 -7.00 PAS 7.39  
V21 -5.60 PAS 78.91  
Tacrine* -6.40 CAS 20.51  
Propidium* -5.48 PAS 95.81  
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                    Table 3.6: The molecular interactions of compounds identified from virtual screening. 
Molecular Interactions Compound No. 
in 
cluster 
Hydrogen 
bonds 
length (Å) 
Residues involved 
in hydrogen 
bonding 
 
Residues involved 
in hydrophobic 
interaction 
 
Residues involved 
in van der waals 
interaction 
 
Residues involved 
in Pi-pi / Pi-sigma / 
Pi-cation 
interaction (A°) 
Binding 
energy 
(kcal/mol) 
Trp286 Leu289 Glu292 Trp286 Leu289 Val294 Pi-sigma -8.72 
Val294 Phe295 Phe297 Phe295 Arg296 Phe297 Trp286-C18 (1.835)  
Phe338 Tyr341 Gly342 Phe338 Tyr341 Gly342   
V1 1 2.95 
3.03 
O2…..OH-Tyr337 
O1…..N-Ser293 
Val365   Val365     
Tyr72 Trp286 Phe295 Tyr72 Tyr124 Phe295 Pi-pi -8.51 
Phe297 Tyr337 Phe338 Arg296 Phe297 Tyr337 ligand-Trp286  
V2 8 2.93 O1…..OH-Tyr124 
Tyr341   Phe338 Tyr341  Pi-sigma  
          Tyr341-C3 (1.781)  
Tyr72 Tyr124 Trp286 Tyr72 Tyr124 Val294 Pi-sigma -8.34 V3 14 2.77 O2…..N-Phe295 
Phe297 Phe338 Tyr341 Phe297 Tyr337 Tyr341 Trp286-C7 (1.764)  
Tyr124 Trp286 Leu289 Trp286 Val294 Phe295 - -8.30 
Glu292 Ser293 Val294 Arg296 Phe297 Phe338   
Phe295 Phe297 Phe338 Tyr341     
V4 9 - - 
Tyr341        
Tyr72 Trp286 Phe297 Tyr124 Val294 Phe297 Pi-pi -7.92 V5 6 2.72 O3…..N-Phe295 
Phe338 Tyr341  Tyr337 Phe338 Tyr341 ligand-Trp286  
          Pi-sigma  
          Tyr341-C16  (1.712)  
Tyr72 Asp 74 Tyr 124 Tyr72 Tyr124 Trp286 Pi-pi -7.76 
Trp286 Val294 Arg296 Val294 Phe297 Phe338 ligand-Trp286  
Phe297 Tyr341 Tyr337    Pi-sigma  
V6 10 2.84 O1…..N-Phe295 
Phe338      Tyr341-C15  (1.670)  
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Molecular Interactions Compound No. 
in 
cluster 
Hydrogen 
bonds 
length (Å) 
Residues involved 
in hydrogen 
bonding 
 
Residues involved 
in hydrophobic 
interaction 
 
Residues involved 
in van der waals 
interaction 
 
Residues involved 
in Pi-pi / Pi-sigma / 
Pi-cation 
interaction (A°) 
Binding 
energy 
(kcal/mol) 
Tyr124 Trp286 Leu289 Tyr124 Trp286 Leu289 - -7.75 
Gln291 Glu292 Val294 Gln291 Val294 Phe295   
Phe295 Arg296 Phe297 Arg296 Phe297 Phe338   
V7 4 2.71 
3.12 
3.19 
O3…..N-Ser 293 
O3…..O-Ser 293 
O4….. O-Ser 293 
 Tyr337 Phe338 Tyr341 Tyr341     
Tyr72 Tyr124 Trp286 Tyr72 Tyr124 Trp286 - -7.50 
Leu289 Val294 Arg296 Val294 Arg296 Phe297 Pi-sigma  
Phe297 Tyr337 Phe338 Tyr337   Trp286-C20 (1.942)  
V8 7 2.90 O1…..N-Phe295 
Tyr341        
Tyr72 Asp74 Tyr124 Tyr72 Trp286 Leu289 Pi-pi -7.35 
Trp286 Leu289 Pro290 Gln291 Glu292 Phe297 ligand-Trp286  
Gln291 Glu292 Val294 Tyr341   ligand-Tyr341  
Phe295 Arg296 Phe297      
V9 3 2.65 N2…..O-Ser293 
Phe338 Tyr341       
Tyr124 Trp286 His287 Tyr124 Trp286 Leu289 Pi-sigma -7.34 
Leu289 Pro290 Gln291 Pro290 Gln291 Glu292 Tyr341-C17 (1.707)  
Glu292 Val294 Phe295 Phe297 Tyr337 Phe338   
Phe297 Tyr337 Phe338      
V10 
 
 
 
 
7 2.70 
3.10 
O2…..N-Arg296 
N1…..O-Ser293 
Tyr341        
Tyr124 Trp286 Leu289 Tyr124 Trp286 Leu289 - -7.31 
Phe297 Val294 Tyr337 Phe297 Tyr337 Phe338   
V11 3 2.96 
3.09 
3.12 
3.17 
3.18 
3.39 
3.51 
3.61 
3.82 
N1…..O-Tyr341 
O2…..N-Arg296 
O3…..O-Arg296 
O2…..N-Phe295 
O1…..N-Phe295 
O3…..O-Ser293 
O3…..N-Arg296 
O3…..N-Phe295 
O3.....OG-Ser293 
Phe338  
 
 
 
 
 
 
     
 
 
 
  
          (continued) 
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Molecular Interactions Compound No. 
in 
cluster 
Hydrogen 
bonds 
length (Å) 
Residues involved 
in hydrogen 
bonding 
 
Residues involved 
in hydrophobic 
interaction 
 
Residues involved 
in van der waals 
interaction 
 
Residues involved 
in Pi-pi / Pi-sigma / 
Pi-cation 
interaction (A°) 
Binding 
energy 
(kcal/mol) 
Trp286 His287 Leu289 His287 Leu289 Gln291 - -7.29 
Pro290 Gln291 Ser293 Ser293 Val294 Phe295   
Val294 Phe295 Arg296 Arg296 Phe297 Phe338   
V12 2 2.94 
3.83 
O2…..OH-Tyr124 
O2…..OH-Tyr337 
Phe297 Phe338 Tyr341 Tyr341     
Tyr72 Tyr124 Trp286 Tyr72 Phe295 Arg296 - -7.25 
Val294 Phe295 Phe297 Phe297 Phe338    
V13 7 - - 
Tyr337 Phe338 Tyr341      
Tyr124 Trp286 Leu289 Trp286 Leu289 Gln291 - -7.23 
Val294 Phe295 Arg296 Val294 Phe295 Arg296   
Phe297 Tyr337 Phe338 Phe297 Phe338 Tyr341   
V14 9 3.01 O2…..OG-Ser293 
Tyr341        
Tyr124 Trp286 Leu289 Tyr124 Trp286 Leu289 Pi-pi -7.16 
Val294 Phe295 Tyr337 Phe297 Phe338 Tyr341 ligand-Trp286  
V15 14 2.81 
2.82 
2.96 
O1.....N-Phe295 
O1.....N-Arg296 
N1.....OG-Ser293 Phe338 Tyr341       
Tyr72 Tyr124 Trp286 Tyr72 Tyr124 Trp286 - -7.13 
Leu289 Val294 Arg296 Val294 Arg296 Phe297   
Phe297 Tyr337 Phe338 Tyr337 Tyr341    
V16 3 2.88 O1…..N-Phe295 
Tyr341        
Tyr72 Trp86 Gly120 Trp86 Gly120 Tyr133 Pi-cation -7.09 
Gly121 Tyr133 Glu202 Tyr341 Trp286 Phe295 Tyr341-N1  
Ser203 Trp286 Val294 Arg296 Phe297 Tyr337 His447:NE2 - ligand  
Phe295 Arg296 Phe297 Phe338 Tyr341 His447   
Tyr337 Phe338 Tyr341      
His447 Gly448 Tyr449      
V17 1 2.75 
2.77 
N1…..OH-TYR124 
O3…..OH-TYR124 
Ile451        
  
                                                                                                                                                                                                          (continued) 
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Molecular Interactions Compound No. 
in 
cluster 
Hydrogen 
bonds 
length (Å) 
Residues involved 
in hydrogen 
bonding 
 
Residues involved 
in hydrophobic 
interaction 
 
Residues involved 
in van der waals 
interaction 
 
Residues involved 
in Pi-pi / Pi-sigma / 
Pi-cation 
interaction (A°) 
Binding 
energy 
(kcal/mol) 
V18 1 -  Tyr72 Asp74 Trp86 Trp86 Gly120 Gly121 Pi-pi -7.08 
    Gly120 Gly121 Gly122 Ser125 Gly126 Tyr133 ligand-Trp286  
    Tyr124 Ser125 Gly126 Gly202 Ser203 Trp286 Tyr341-ligand  
    Leu130 Tyr133 Glu202 Val294 Phe295 Arg296   
    Ser203 Trp286 Val294 Phe297 Tyr337 Phe338   
    Phe295 Phe297 Tyr337 Tyr341     
    Phe338 Tyr341 His447      
    Gly448        
Tyr72 Tyr124 Trp286 Tyr124 Trp286 Leu289 Pi-sigma -7.00 
Leu289 Val294 Phe295 Val294 Arg296 Phe297 Trp286-C19 (1.765)  
Arg296 Phe297 Tyr337 Phe338   Pi-cation  
V19 2 3.34 
3.44 
O3…..O-Ser293 
O3…..O-Tyr341 
 
Phe338      Trp286-N1  
          Trp286-N1  
Tyr72 Asp74 Tyr124 Tyr72 Asp74 Tyr124 - -7.00 
Trp286 Leu289 Ser293 Trp286 Leu289 Val294   
Val294 Phe295 Arg296 Phe297 Tyr337 Phe338   
Phe297 Tyr337 Phe338      
V20 
 
 
 
4 - 
 
- 
 
Tyr341        
Thr75 Leu76 Tyr124 Leu76 Tyr124 Trp286 Pi-Pi -5.60 
Trp286 Val294 Arg296 Val294 Phe297 Tyr337 ligand-Trp286  
Phe297 Tyr337 Phe338 Phe338 Tyr341  ligand- Tyr72  
V21 1 2.95 
2.98 
O1…..OH-TYR72 
O2…..N-Phe295 
Tyr341      Pi-sigma  
          Trp286-C7  
 
                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                (continued) 
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In this study, in order to find PAS binding ligands for virtual screening, the 
ligands decamethonium (both PAS and CAS binder), decidium and MF268 (PAS 
binders) were used as a backbone structure to download ligands from ZINC database. 
Tables 3.5 and 3.6 show docking results for top twenty one ligands from virtual 
screening. The lowest binding energy that could be obtain was -8.72 kcal/mol for 
compound V1. This value is much better than the binding energy for the ligands 
decamethonium, decidium and MF268 which were 3.54 kcal/mol, -4.30 kcal/mol and -
3.94 kcal/mol, respectively.  
 
Molecular interaction studies indicated that all ligands bound to PAS of the 
enzyme near the aromatic residue Trp286 except compound V17 and compound V18 
which bound to PAS and CAS of the enzyme (Table 3.5). Residues that mainly involved 
in hydrophobic interaction are Trp286, Phe295 (except for compounds V3, V5, V6, V8, 
V11, V16 and V21), Phe297 (except for compound V15), Tyr337 (except for 
compounds V1, V3, V4, V5, V9 and V12) and Phe338. Meanwhile, residues such as 
Trp286 (except for V2, V3, V5, V12 and V13), Phe297 and Tyr341 (except for V6, V8, 
V10, V11, V13, V19 and V20) are mostly involved in van der waals interaction.  
 
Molecular interaction investigation also suggested that the residues Tyr72, 
Tyr124, Ser293, Phe295, Arg296, Tyr337 and Tyr341 are important for the hydrogen 
bonding between ligands and the protein. The residues Trp286 and Tyr341 are 
contributing for pi-sigma interaction, residues Tyr72, Trp286 and Tyr341 are involved in 
pi-pi interaction whereas the residues Trp286, Tyr341 and His447 are contributing for 
pi-cation interaction between the ligand and the protein.  
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Other than the usage of AChE inhibitors in the treatment of AD, peripherally 
acting AChE inhibitors are used in conditions such as glaucoma, constipation, 
spasmolysis, anaesthesiology and myasthenia gravis (Komloova et al., 2011). These 
conditions can be treated with peripherally acting AChE inhibitors that contain a 
positive charge in their structure (Komloova et al., 2011). Since these compounds do not 
penetrate blood-brain barrier, thus avoiding side effects. In this study, several 
compounds that have been identified from virtual screening contain a positive charge in 
their structure and therefore have potential for these other applications.  
 
3.4 CONCLUSION 
In this study our interest was to find PAS binding ligands. The blind docking 
results using a crystal structure of hAChE in complex with fasciculin II (PDB ID: 1b41) 
have shown that most of the PAS ligands bound near the aromatic residue Trp286. This 
is in agreement with site directed mutagenesis studies. The structure obtained from this 
crystal structure was found to be the most suitable for identifying PAS ligands and was 
chosen for virtual screening compared with other AChE model structures.  
 
Based on the molecular interaction studies on the top twenty one ligands from 
the virtual screening, it can be concluded that Trp286, Phe295, Phe297, Tyr337 and 
Phe338 are mainly involved in hydrophobic contacts, the residues Trp286, Phe297 and 
Tyr341 are mostly contributing for van der waals interaction, residues Tyr72, Tyr124, 
Ser293, Phe295, Arg296, Tyr337 and Tyr341 are contributing for the hydrogen bonding 
while the residues such as Tyr72, Trp286, Tyr341, and His447 are important in pi-
sigma, pi-pi and pi-cation interactions.  
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CHAPTER 4: OPTIMISATION OF HUMAN ACETYLCHOLINESTERASE 
INHIBITION ASSAY AND AMYLOID BETA PEPTIDE AGGREGATION 
ASSAY  
 
4.1 INTRODUCTION 
The principal biological role of acetylcholinesterase (AChE) (acetylcholine 
hydrolase, E.C. 3.1.1.7) is termination of impulse transmission at cholinergic synapses 
by rapid hydrolysis of the neurotransmitter acetylcholine (ACh) (Dvir et al., 2010). 
 
CH3COOCH2CH2N+(CH3)3 + AChE             CH3CO-AChE + HOCH2CH2N+(CH3)3 
CH3COO- + H+ + AChE 
 
           The catalytic activity of AChE is very high with each molecule of AChE 
degrading about 5000 molecules of acetylcholine (ACh) per second. The choline 
produced by the action of AChE is recycled, and transported, through reuptake, back 
into nerve terminals where it is used to synthesize new ACh molecules. 
 
 The standard method for determination of AChE activity is Ellman’s method 
(Ellman et al., 1961), which measures the rate of production of thiocholine as 
acetylthiocholine is hydrolyzed. This is accomplished by the reaction of the thiol group 
with 5: 5-dithiobis-2-nitrobenzoate ion (DTNB) to produce the intense yellow coloured 
anion of 5-thio-2-nitro-benzoic acid. 
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Figure 4.1: Structures of DTNB and Thioflavin T. 
 
 
 Amyloid peptide aggregation can be determined using Thioflavin T (ThT) 
(Figure 4.1), a cationic benzothiazole dye that shows enhanced fluorescence upon 
binding to amyloid fibrils (Khurana et al., 2005). The fluorescence spectra and binding 
properties of ThT were first characterized by Naiki et al. (1989), Naiki et al. (1990), 
Naiki et al. (1991), LeVine (1993) and LeVine (1997). They demonstrated that, upon 
binding of fibrils, ThT displays a dramatic shift of the excitation maximum (from 385 
nm to 450 nm) and the emission maximum (from 445 nm to 482 nm) and that ThT 
fluorescence originates only from the dye bound to amyloid fibrils (Naiki et al., 1989; 
Levine, 1993). 
 
In the current study, the Ellman assay and Thioflavin T-Based Fluorometric 
assay were adopted and optimized based on the method developed by Ellman (Ellman 
et al., 1961) and LeVine (Levine, 1993), respectively. 
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4.2 MATERIALS 
Acetylcholinesterase from human recombinant (2,419 U/mg), lyophilized powder (E.C. 
No. 3.1.1.7), acetylthiocholine iodide (ATChI), 5, 5’-dithiobis[2-nitrobenzoic acid] 
(DTNB), tacrine hydrochloride (A79922), propidium iodide (P4170), thioflavin T, di-
sodium hydrogen orthophosphate dodecahydrate (Na2HPO4.12H2O), sodium 
dihydrogen orthophosphate (NaH2PO4.2H2O), sodium hydroxide (NaOH), glycine, 
hydrochloric acid (HCl) 37%, dimethyl sulfoxide (DMSO), methanol (MeOH) and 
ethanol (EtOH) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
chemicals were of analytical grade. Amyloid beta (Aß) peptide (1-40), lyophilized from 
HFIP solution was purchased from Anaspec (Fremont, CA, USA). Instruments used 
included a uv / fluorescence spectrophotometer and multiplate reader (Tecan Infinite 
M200). 
 
4.3 METHODS 
4.3.1 Optimisation of human acetylcholinesterase (hAChE) inhibition assay 
4.3.1.1 Buffer preparation 
 
 0.1 M sodium phosphate buffer was prepared by mixing 47.35 mL of 0.2 M 
dibasic sodium phosphate and 2.65 mL of 0.2 M monobasic sodium phosphate. The 
volume was then made up to 100 mL with deionised water and adjusted to pH 8.0 with 
concentrated hydrochloric acid.  
 
4.3.1.2 Enzyme preparation 
 Acetylcholinesterase from human recombinant (2,419 U/mg) was dissolved in 
0.1 M sodium phosphate buffer pH 8.0 and the aliquots were kept at – 80 °C.  
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4.3.1.3 Acetylthiocholine iodide (ATChI) preparation 
 0.6 mM stock solution of acetylthiocholine iodide was freshly prepared by 
dissolving 1.0 mg of acetylthiocholine iodide powder in 6 mL of 0.1 M sodium 
phosphate buffer pH 8.0.  
 
4.3.1.4 5,5’-dithiobis [2-nitrobenzoic acid] (DTNB) preparation 
           0.63 mM stock solution of 5,5’-dithiobis [2-nitrobenzoic acid] was freshly 
prepared by dissolving 0.5 mg of 5,5’-dithiobis [2-nitrobenzoic acid] powder in 1.23 
mL of 0.1 M sodium phosphate buffer pH 8.0. 
 
4.3.1.5 Assay 
 The AChE inhibition assay was performed in 96 well plates by the method of 
Ellman et al. (1961) and Li et al. (2009) with minor modifications, using 
acetylthiocholine as a substrate. 5, 5’-dithiobis [2-nitrobenzoic acid](DTNB) was used 
to measure cholinesterase activity. 110 µL of sodium phosphate buffer (pH 8.0) was 
added to the each well followed by 20 µL of sample, 50 µL of DTNB (0.126 mM) and 
20 µL of AChE enzyme (0.6 u/ml). The mixture was incubated for 20 minutes at 37 ºC. 
The reaction was then initiated by the addition of 50 µL (0.120 mM) of 
acetylthiocholine iodide. The hydrolysis of acetylthiocholine was monitored by 
measuring the absorbance due to yellow 5-thio-2-nitrobenzoate anion at a wavelength 
of 412 nm every 30 s for 25 min. Each assay was performed in triplicate. 
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                                                                                           Incubate at 37 ºC, 20 min 
 
 
 
 
 
 
 
Figure 4.2: The flow chart of the protocol optimised anticholinesterase assay. 
 
aFinal DMSO concentration of 0.1 % v/v 
bFinal DTNB concentration of 0.126 mM 
cFinal AChE enzyme concentration of 0.6 u/ml 
  dFinal acetylthiocholine iodide concentration of 0.120 mM 
  
 
 
 
 
 
 
110 µL of sodium phosphate buffer (pH 8.0), 0.1 M 
+ 
20 µL of buffer/standard inhibitor/compoundsa 
+ 
50 µL of DTNBb 
+ 
20 µL of AChE enzymec 
Initiate reaction: 
+ 
50 µL of acetylthiocholine iodided 
Read absorbance at 412 nm every 30 s for 25 min 
using a 96-well microplate plate reader 
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4.3.1.6 Data analysis 
The percent inhibition was calculated by the following expression: (E–S)/E x 
100), where E is the activity of the enzyme without test compound and S is the activity 
of the enzyme with test compound. Data from concentration-inhibition experiments of 
the inhibitors were transformed by nonlinear regression analysis, which gave estimates 
of the IC50 (concentration of drug producing 50 % inhibition of enzyme activity 
inhibition). Tacrine and propidium iodide were used as standard inhibitors. The 
computer program PRISM® Software, version 3.0 (GraphPad Software, Inc, San Diego, 
USA) was used to analyze these data. 
 
4.3.2 Optimisation of Aß peptide aggregation assay  
4.3.2.1 Buffer preparation  
 0.215 M sodium phosphate buffer was prepared by mixing 47.35 mL of 0.43 M 
dibasic sodium phosphate and 2.65 mL of 0.43 M monobasic sodium phosphate. The 
volume was then made up to 100 mL with deionised water and adjusted to pH 8.0 with 
concentrated hydrochloric acid.  
 
 50 mM glycine-sodium hydroxide (Gycine-NaOH) buffer was prepared by 
dissolving 0.375 g of glycine in 70ml of diionised water. Then, 2 mL of 0.2 M NaOH 
solution was added into the glycine solution. The volume was then made up to 100 mL 
with deionised water and adjusted to pH 8.5 with concentrated hydrochloric acid.  
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4.3.2.2 Preparation of Aß peptide stock solution  
   231 µM Aß peptide stock solution was prepared by dissolving 1 mg of Aß 
peptide (1-40) (lyophilized from HFIP solution) in DMSO. The solution was then 
aliquoted and stored at –20 °C until use.  
 
4.3.2.3 Preparation of Thioflavin T (Th-T) 
   30 µM stock solution of Th-T was prepared by dissolving 0.28 mg of Th-T in 29.3 
mL of deionised water. Then 3 µM of Th-T solution was prepared by diluting 500 µL of the 
stock solution with 500 µL of 50 mM glycine-NaOH buffer pH 8.5.  
 
4.3.2.4 Assay 
The Aß peptide aggregation assay was performed by the method of LeVine 
(1993) and Munoz-Ruiz et al. (2005) with minor modifications. The protocol of the 
assay as described here is based on the optimised parameters of section 4.4. Aß peptide 
(1-40), lyophilized from HFIP solution, was dissolved in DMSO to prepare a stock 
solution. Aliquots of Aß in DMSO were then incubated in constant rotation for 24 hours 
at room temperature in 0.215 M sodium phosphate buffer (pH 8.0) at a final Aß 
concentration of 5 µM in the presence or absence of compounds or propidium at 100 
µM, used as a reference. To quantify amyloid fibril formation, the thioflavin T 
fluorescence method was used. Fluorescence was measured at 440 nm (λ excitation) and 
485 nm (λ emission). To determine amyloid fibril formation, after incubation, the 
solution containing Aß or Aß plus AChE inhibitors were added to 50 mM gycine-NaOH 
buffer, pH 8.5, containing 3 µM thioflavin T in a final volume of 150 µL. Each assay 
was performed in triplicate.  
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4.3.2.5 Data analysis 
The percent aggregation was calculated by the following expression: 100 – 
(IFi/IFox100) where, IFi and IFo are the fluorescence intensities obtained for Aß in the 
presence and in the absence of inhibitor, respectively, after subtracting the fluorescence 
of the respective blanks.  
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Figure 4.3: The flow chart of the protocol of amyloid beta peptide aggregation assay. 
 
aFinal amyloid beta peptide concentration of 5 µM 
bFinal DMSO concentration of 0.5% v/v 
 
 
 
 
 
 
 
 
 
 
 
25 µL of amyloid beta peptidea 
+ 
20 µL [Solvent control (DMSO)] / 20 µL [Standard inhibitor (Propidium iodide)]/  
20 µL [Test compounds ]b 
Incubation at 25 ◦C in the dark, in constant agitation at 100 rpm for 24 hours 
Determination of amyloid fibril formation: 
 + 105 µL of 50 mM gycine-NaOH buffer, pH 8.5, containing 3 µM of thioflavin T  
Read the fluorescence at 440 nm (excitation wavelength) and 485 nm (emission) 
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4.4 RESULTS AND DISCUSSION 
4.4.1 Optimisation of hAChE inhibition assay 
4.4.1.1 Determination of absorbance wavelength 
Absorbance scanning was carried out from 0 to 60 min to select a suitable 
wavelength for the Ellman assay (Figure 4.4 (a)). The color development increased 
linearly until 60 minutes (Figure 4.4 (b)) at 412 nm as reported earlier by Ellman et al. 
(1961). Therefore the wavelength 412 nm was chosen as the optimum wavelength for 
this assay.   
(a)  
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
Figure 4.4: (a) Absorbance scanning (300 nm – 550 nm), (b) Absorbance at 412 nm 
against time measured over 60 min. 
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4.4.1.2 Optimisation of enzyme concentration 
The effect of enzyme concentration on absorbance was determined using 
enzyme concentrations between 0 u/ml to 1.24 u/ml (Figure 4.5). It was observed that 
all concentrations of enzyme showed a linear response until 1 hour. The maximum 
absorbance that could reach by enzyme concentrations 0 to 0.31 u/ml until 1 hour was 
about 0.15 OD/min which was too low, meanwhile the OD/min at 1 hour was too high 
(>0.7) at enzyme concentration of 1.24 u/ml. Therefore, 0.62 u/ml enzyme was chosen 
as the optimum enzyme concentration for this assay.   
 
 
 
 
 
 
 
 
Figure 4.5: Absorbance against time at varying enzyme concentrations. Each data point 
is expressed as mean ± standard deviation (n=3). 
 
 
4.4.1.3 Optimisation of substrate concentration 
According to the Michaelis – Menten kinetics model, the Km is the substrate 
concentration which results in an initial reaction velocity that is one-half the maximum 
velocity determined under saturating substrate concentration. In order for competitive 
inhibitors to be identified in a competition experiment that measures IC50 values, a 
substrate concentration around or below the Km value must be used.  
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(a) 
 
 
 
 
 
  
 
 
Figure 4.6 (a): Absorbance against time at varying substrate concentrations. Each data 
point is expressed as mean ± standard deviation (n=3). 
 
(b) 
 
 
 
 
 
 
 
 
Figure 4.6 (b): Estimation of Km value for the substrate. 
Michaelis-Menten kinetics (relationship between initial rate and substrate 
concentration). Best-fit value: Vmax = 0.042 mM/min, Km = 0.123 mM, R² = 0.9983. 
 
           The concentration of substrate acetylthiocholine iodide was varied from 0–1 mM 
with a fixed concentration of enzyme (0.6 u/ml) to determine the Km value of the 
substrate. All concentrations of acetylthiocholine iodide showed a linear response until 
1 hour (Figure 4.6 (a)). The absorbances at 25 minutes were used to determine the rate 
of reaction and Km value (Figure 4.6 (b)). The initial velocity (vo) for each reaction 
progress curves is equivalent to the slope of the line which is defined as the change in 
the amount of product formed divided by the change in time. The Km value was 
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estimated as 0.12 mM and this value was used as the optimum concentration of 
substrate in the experiments that follow. 
 
4.4.1.4 Optimisation of incubation time  
The kinetic reaction was conducted with the enzyme and substrate 
concentrations fixed at 0.62 u/ml and 0.12 mM, respectively at two different 
temperatures, 25 ˚C (Figure 4.7(a)) and 37 ˚C (Figure 4.7(b)) for 1 hour to determine 
the optimum incubation time for this assay. 
 
(a) 25 ºC 
 
 
 
 
 
 
(b) 37 ºC 
 
 
 
 
 
 
Figure 4.7 (a) & (b): Optimisation of incubation time at 25 ºC & 37 ºC. Each data point 
is expressed as mean ± standard deviation (n=3). 
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All the incubation times showed a linear response until 1 hour. An incubation 
time of 20 minutes was chosen for the optimal reaction since there is not much 
difference in the changes of absorbance at various incubation times. 
 
4.4.1.5 Optimisation of incubation temperature  
The kinetic reaction was conducted for 1 hour with the enzyme and substrate 
concentrations fixed at 0.62 u/ml and 0.12 mM, respectively at two different 
temperatures, 25 ˚C and 37 ˚C (Figure 4.8) after 20 minutes of incubation. 
 
 
 
 
 
 
      
 
Figure 4.8: Optimisation of incubation temperature. Each data point is expressed as 
mean ± standard deviation (n=3). R² = 0.9977 (25 ºC) and R² = 0.9912 (37 ºC). 
 
Reactions at both temperatures were linear until 1 hour. Since 37 ˚C is an 
ambient temperature for most biological reactions, it was chosen as the incubation 
temperature for optimal reaction. 
 
4.4.1.6 Optimisation of solvent concentration 
The kinetic reaction was conducted for 40 minutes, after 20 minutes of 
incubation at 37 ˚C (with the enzyme and substrate concentrations fixed at 0.62 u/ml 
and 0.12 mM, respectively and varying concentrations of dimethyl sulfoxide (DMSO), 
methanol (MeOH), and ethanol (EtOH) (0 % –1.0 % v/v)). 
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(a) Effect of DMSO 
 
 
 
 
 
 
 
 
(b) Effect of methanol 
 
 
 
 
 
 
 
Figure 4.9 (a) & (b): Optimisation of solvent concentration. Each data point is expressed 
as mean ± standard deviation (n=3). R² = 0.9384 and 0.9739 for DMSO and methanol, 
respectively. 
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(c) Effect of ethanol 
 
 
  
 
 
 
 
Figure 4.9 (c): Optimisation of solvent concentration. Each data point is expressed as 
mean ± standard deviation (n=3). R² = 0.9513. 
 
The percentage of inhibition increased in a dose dependent manner with 
percentage of organic solvent (Figure 4.9 (a)–(c)). The maximum percentage of 
inhibition was observed at around 25 % at 0.25 % of v/v for DMSO, 14 % and 20 % at 
1.0 % of v/v for MeOH and EtOH. DMSO is a universal solvent and can be used to 
dissolve most of the compounds. Therefore a final concentration of DMSO up to 0.1 % 
can be used with maximum percentage of inhibition at around 10–15 %. 
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4.4.1.7 Assay validation with standard inhibitors 
The assay was validated with standard inhibitors tacrine and propidium using 
the optimised parameters as described earlier. The graph of % inhibition reaction 
reached a plateau at 95 % for tacrine and the IC50 was determined as 0.26 µM (Figure 
4.10). 
 
 
 
 
 
 
 
 
Figure 4.10: Percentage inhibition of AChE against concentration of tacrine (0–100 
µM). Each data point is expressed as mean ± standard deviation (n=3). Best-fit value: 
Vmax = 95.40 %, IC50= 0.26 µM, R² = 0.9987. 
 
 
 
 
 
 
 
 
Figure 4.11: Percentage inhibition of AChE against concentration of propidium iodide (0–
100 µM). Each data point is expressed as mean ± standard deviation (n=3). Best-fit value: 
Vmax = 91.24 %, IC50= 11.20 µM, R² = 0.9929. 
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This value was comparable to the value previously reported for tacrine, 0.50 µM 
(Korabecny et al., 2011). The graph of % inhibition for propidium showed maximum 
inhibition of 91 % and the IC50 was determined as 11.20 µM (Figure 4.11). 
 
4.4.2 Optimisation of Aß peptide aggregation assay  
4.4.2.1 Fluorescence intensity scanning  
The Aß peptide aggregation assay was conducted as described in section 
4.3.2.4. In order to find a suitable wavelength for fluorescence scanning, wells with 
various concentrations of Aß peptide (0, 0.03, 0.08, 0.15, 0.3, 0.6, 1.2, 2.4, 5, 10, 20 and 
40 µM) were prepared. The fluorescence excitation spectrum was recorded between 400 
to 470 nm (with emission fixed at 550 nm) while the emission scan was performed from 
475 to 550 nm (with excitation wavelength fixed at 440 nm). The excitation and 
emission peaks that were obtained for the well that contained a final concentration of 
Aß peptide of 10 µM were 440 nm and 485 nm, respectively (Figures 4.12 (a) & (b)) 
(More concentrated wells with fixed concentrations of 20 µM and 40 µM of Aß peptide 
gave signal overflow). These values were almost similar with the reported range 
(Bartolini et al., 2003). 
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 (a) Excitation scanning 
 
 
 
 
 
 
         
(a) Emission scanning 
 
 
 
 
 
 
 
Figure 4.12 (a) & (b): Fluorescence intensity of thioflavin T ranged from wavelength 
of 400 nm to 470 nm (excitation scan), 470 nm to 550 nm (emission scan). 
 
The excitation and emission peaks that were obtained above were applied 
further to determine the Z-position height and the value of optimal gain. Z-position 
scans were performed for both a signal and blank well in order to detect the volume in 
the well and to achieve the maximum signal to blank ratio thus increase the sensitivity 
of the instrument towards assay sample. The optimal gain value was achieved in order 
to improve the accuracy in fluorescence readings. The value of optimal Z-position 
height and optimal gain value that could obtain were 18325 µM and 166, respectively 
and these values were used in every subsequent experiment to make sure the readings 
were consistent.  
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4.4.2.2 Optimisation of Aß peptide concentration 
The assay was conducted as described in section 4.3.2.4 using various 
concentrations of Aß peptide (0, 0.03, 0.08, 0.15, 0.3, 0.6, 1.2, 2.4, 5, 10, 20 and 40 
µM). Hexafluoroisopropanol (HFIP) has been shown to break down β-sheet structure, 
disrupt hydrophobic forces in aggregated amyloid preparations, and promote α-helical 
secondary structure (Bartolini et al., 2003). Therefore, in order to prevent pre-
aggregation in the initial solution, Aß peptide (1 - 40), lyophilized from HFIP solution 
was used and then a stock solution was prepared by dissolving it in 100 % DMSO. The 
reason for stock solution prepared in 100 % DMSO was, at this concentration, DMSO 
does not promote thioflavin T fluorescence (Sabate et al., 2008) and contributes only 
minimum aggregation (Shen & Murphy, 1995; Bartolini et al., 2003).  
 
 
 
 
 
 
 
 
Figure 4.13: Graph of fluorescence intensity against Aß peptide (1-40) concentration. 
Each data point is expressed as mean ± standard deviation (n=3). 
 
 
Figure 4.13 shows the non-linear relationship between fluorescence intensity 
and Aß peptide concentration. The fluorescence intensity increased until a concentration 
of 5 µM of Aß peptide concentration and slowly started to reach plateau at a 
concentration of 10 µM. At the final concentrations of 20 µM and 40 µM of Aß peptide 
(data not shown in graph), the signal gave overflow. Since the concentration of 5 µM 
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was quite near to the reported value (Levine, 1993) and (Munoz-Ruiz et al., 2005), it 
was chosen as the optimum concentration for the Aß peptide assay and was used in 
subsequent experiments. 
 
4.4.2.3 Effect of solvent on Aß peptide aggregation 
The experiment was conducted as described in section 4.3.2.4 using a fixed 
concentration of Aß (5 µM) and various concentrations of DMSO (0–3 % v/v) as 
sample (Figure 4.14 (a) & (b)). 
 
(a)                  
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
Figure 4.14 (a) & (b): Graphs of fluorescence intensity / % inhibition of Aß peptide 
aggregation against concentration of DMSO. 
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1 % of DMSO showed negative inhibition, whereas 0.5 % DMSO demonstrated 
the lowest inhibition value compared to the 2 and 3 % of DMSO. Avona test 
(Bonferroni’s multiple comparison test) was carried out to determine whether there was 
any significant difference between the inhibition effects for 0.5, 1, 2 and 3 % of DMSO. 
The p value that was obtained was 0.83 (p > 0.05). This confirmed that there was no 
significant difference between 0.5, 1, 2 and 3 % of DMSO. Therefore 0.5 % DMSO (the 
lowest among 0.5, 1, 2 and 3 % of DMSO) was selected as the desired solvent 
concentration during preparation of different concentrations of test compounds. 
 
4.4.2.4 Assay validation with standard inhibitor (Propidium Iodide)  
The assay was validated with the standard inhibitor, propidium iodide using the 
optimised parameters as described earlier. Propidium iodide is known to be a potent 
inhibitor of Aß peptide aggregation (Munoz-Ruiz et al., 2005) and also does not affect 
the fluorescence intensity of ThT as the iodide does not exhibit a quenching effect on 
ThT (Bartolini et al., 2003). Therefore, it was selected as the standard inhibitor in this 
assay. 
 
 
 
 
 
 
 
 
 
Figure 4.15: Graph of % inhibition of Aß peptide aggregation against concentration of 
propidium iodide. Each data point is expressed as mean ± standard deviation (n= 3). 
Best-fit value: Vmax = 94.20 %, IC50= 8.23 µM, R² = 0.9972. 
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 Based on Figure 4.15, the reaction reached a plateau at 90 % inhibition and the 
IC50 of propidium was determined as 8.23 µM.  
 
4.5 CONCLUSION 
The human acetylcholinesterase inhibition assay was conducted by modifying 
the method of Ellman et al. (1961). Parameters such as enzyme concentration, substrate 
concentration, incubation time, incubation temperature and solvent were optimised. 
Different concentrations of substrate were used to determine the Km value. This Km 
value was used as the substrate concentration for this assay for competitive inhibitors to 
be identified in a competition experiment that measures IC50 values. The assay was 
validated with standard inhibitors to determine the assay reliability. In Chapter 5, 
compounds derived from the virtual screening study will be tested using this assay. 
 
The Aß peptide assay was performed following the method of LeVine (1993) 
and Munoz-Ruiz et al. (2005) with minor modifications. Fluorescence intensity 
scanning was conducted followed by optimisation of Aß peptide concentration and 
determination of solvent concentration. The assay was validated with a standard 
inhibitor to determine the assay reliability. In Chapter 5, compounds derived from the 
virtual screening study that show promising anticholinesterase activity, will be tested 
using this assay. 
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CHAPTER 5: EVALUATION OF COMPOUNDS IDENTIFIED FROM 
VIRTUAL SCREENING AS INHIBITORS OF ACETYLCHOLINESTERASE 
AND AMYLOID BETA PEPTIDE AGGREGATION 
 
5.1 INTRODUCTION 
In the present study, a number of the compounds identified from virtual 
screening were triterpenes and steroids. Previous studies have discovered that some 
triterpenes and steroids are potential acetylcholinesterase (AChE) inhibitors (Table 
5.1). For an example, Kvaltinova et al. (1991) has reported that buxaminol-E, a steroidal 
alkaloid from B. sempervirens has good inhibitory activity towards AChE. A screening 
of pregnane-type steroidal alkaloids, from Sarcococca hookeriana against AChE was 
performed by Choudhary et al. (2005) and this study has found that these steroidal 
alkaloids had IC50 values between 1.6 and 59.0 µM. In another study, Axillaridine-A, a 
pregnane-type steroidal alkaloid from Sarcococca saligna was reported as potent 
anticholinesterase compound with IC50 value 5.2 µM (Khalid et al., 2004). Steroidal 
alkaloids such as epoxynepapakistamine-A, funtumafrine C and N-methylfuntumine 
from leaves of Sarcococca coriacea also found to have cholinesterase inhibitory with 
IC50 values ranging from 45.8 to >200.0 µM (Kalauni et al., 2002). 
 
Screening was carried out by Atta ur et al. (2001) which resulted in 
identification of effective AChE inhibitors, triterpenoid alkaloids, from Buxus papillosa, 
with IC50 values ranging from 25.4 to 235.0 µM. Another triterpenoid alkaloid, (+)-N-
tigloylbuxahyrcanine has been isolated from Buxus hyrcana and found to be the most 
potent against AChE with IC50 value 443.6 µM (Choudhary et al., 2003). 17-oxo-3-
benzoylbuxadine, benzoylbuxadine, buxhyrcamine, homomoenjodarmine and 
spirofornabuxine are also triterpenoid alkaloids, found from the same plant which 
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exhibited better AChE inhibitory activity with IC50 values ranging from 6.3 to 19.5 µM 
(Ata et al., 2010). In another case, some tetracyclic triterpene with good AChE 
inhibitory profile were also identified by Rouleau et al. (2011). 
 
 In the present study, the Ellman assay was employed to measure the AChE 
activity of the compounds found from virtual screening. Compounds showing the 
greatest anticholinesterase activity were further tested using the thioflavin T-based 
fluorometric assay to study their self-induced amyloid beta (Aβ) peptide aggregation 
inhibitory activity. 
 
Table 5.1: Previous findings on triterpenes and steroids as acetylcholinesterase 
inhibitors. 
 
Compound Plant Activity Reference 
Hookerianamide-d 
Hookerianamide-E 
Hookerianamide-F 
Hookerianamide-G  
Sarcococca 
hookeriana 
1.6–59.0 µM (Choudhary et al., 2005) 
Axillaridine -A Sarcococca saligna 5.2 µM (Khalid et al., 2004) 
Epoxynepapakistamine –
A 
Sarcococca coriacea 45.8– 
 >200.0 µM 
(Kalauni et al., 2002) 
funtumafrine C    
N-methylfuntumine    
Buxakashmiramine 
Buxakarachiamine 
Buxahejramine 
Cyclovirobuxeine-A 
Cyclomicrophylline-A 
Semperviraminol 
Buxus papillosa 25.4–235.0 µM (Atta ur et al., 2001) 
(+)-N-
tigloylbuxahyrcanine 
Buxus hyrcana 443.6 µM (Choudhary et al., 2003) 
17-oxo-3-
benzoylbuxadine 
Buxhyrcamine 
Homomoenjodarmine 
Spirofornabuxine 
Buxus hyrcana 6.3–19.5 µM (Ata et al., 2010) 
Tetracyclic triterpene Synthesized 
compounds 
0.003–> 
10.0 µM 
(Rouleau et al., 2011) 
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5.2 MATERIALS AND METHODS 
     Refer to sections 4.2 and 4.3 
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Human acetylcholinesterase (hAChE) inhibition assay 
The AChE inhibitory effects of the compounds were examined by the method of 
Ellman et al. (1961) using AChE from human recombinant acetylcholinesterase with 
tacrine and propidium as reference standards. The compounds were initially tested at a 
final concentration of 10 µM. Compounds that showed more than 25 % inhibition at 10 
µM were further tested to determine their IC50 values and the data summarized in Table 
5.2.  
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Table 5.2: Anticholinesterase activity of compounds V1–V21 identified from virtual 
screening together with data obtained from the molecular modeling studies. 
 
 
a Values are expressed as mean of triplicate, PAS = Peripheral anionic site, CAS  
= Catalytic site, *Standard inhibitor, - = No activity observed at 10 µM 
 
 
 
 
 
 
 
 
 
 
 
Compound Anti-cholinesterase activity  
(hAChE) 
Docking studies 
 % 
Inhibition  
at 
10 µM a 
IC50 ± SEM  
(µM) 
Ki ± SEM 
(µM) 
Ki 
(µM) 
 
Binding 
site 
V1 27 12.4 ± 1.3 6.2 ± 0.7 0.40 PAS 
V2 19 - - 0.58 PAS 
V3 5 - - 0.77 PAS 
V4 - - - 0.83 PAS 
V5 - - - 1.56  PAS 
V6 3 - - 2.04  PAS 
V7 - - - 2.09  PAS 
V8 - - - 3.16  PAS 
V9 - - - 4.08  PAS 
V10 - - - 4.18  PAS 
V11 1 - - 4.40  PAS 
V12 48 10.4 ± 2.5 5.2 ± 1.3 4.56 PAS 
V13 8 - - 4.86  PAS 
V14 5 - - 5.01  PAS 
V15 5 - - 5.65  PAS 
V16 3 - - 5.90  PAS 
V17 - - - 6.40  PAS & CAS 
V18 90 1.5 ± 0.2 0.8 ± 0.1 6.42  PAS & CAS 
V19 - - - 7.41  PAS 
V20 - - - 7.39  PAS 
V21 38 14.7 ± 4.0 7.4 ± 2.0 78.91  PAS 
Tacrine* 48 0.26 ± 0.01 0.13 ± 0.01 20.51  CAS 
Propidium* 41 11.4 ± 1.3 5.7 ± 0.7 95.81  PAS 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5.1: a) 3D representation of hAChE complex with compound V1 
(ZINC04293012) (purple) at the PAS region of the AChE. b) Ligplot analysis to show 
the molecular interactions (hydrophobic and hydrogen bonds) between the ligand and 
the protein. 
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 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)    
 
 
 
 
 
 
 
 
 
 
Figure 5.2: a) 3D representation of hAChE complex with compound V12 
(ZINC04293010) (green) at the PAS region of the AChE. b) Ligplot analysis to show 
the molecular interactions (hydrophobic and hydrogen bonds) between the ligand and 
the protein. 
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(a)         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: a) 3D representation of hAChE complex with compound V18 
(ZINC01668161) (yellow) at the PAS and CAS region of the AChE. b) Ligplot analysis 
to show the molecular interactions (hydrophobic and hydrogen bonds) between the 
ligand and the protein. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: a) 3D representation of hAChE complex with compound V21 
(ZINC02190312) (blue) at the PAS and CAS region of the AChE. b) Ligplot analysis to 
show the molecular interactions (hydrophobic and hydrogen bonds) between the ligand 
and the protein. 
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 Compounds V1, V12, V18 and V21 showed inhibition of 27 %, 48 %, 90 % and 
38 % at a final concentration of 10 µM, respectively. These compounds were further 
tested in various concentrations (0–100 µM) to estimate the IC50 value. The IC50 of V1, 
V12 and V21 were found to be 12.44 µM, 10.43 µM and 14.69 µM, respectively. The 
IC50 of V18 was determined as 1.54 µM and this value was comparable to the value 
previously reported for V18, 4 µM (Komloova et al., 2011). 
 
  Molecular interaction study (Tables 3.6 & 5.2) (see figures 5.3 (a) & (b)) has 
shown that compound V18 bound to CAS and PAS of the enzyme near the aromatic 
residue Trp86 and Trp286, respectively. Residues that mainly involved in hydrophobic 
interaction are Tyr72, Asp74, Trp86, Gly120, Gly121, Gly122, Tyr124, Ser125, Gly126, 
Leu130, Tyr133, Glu202, Ser203, Trp286, Val294, Phe295, Phe297, Tyr337, Phe338, 
Tyr341, His447 and Gly448. In addition to the hydrophobic contacts, pi-pi interactions 
were also found between the compound V18 and the residues Trp286 and Tyr341 which 
increase the anticholinesterase activity of this compound.  
 
  Docking studies on compounds V1, V12 and V21 (Tables 3.6 & 5.2) (see 
figures 5.1, 5.2 and 5.4) has indicated that these compounds are PAS binders. Molecular 
investigation has shown that the residues Trp286, Phe297, Phe338, Val294 and Tyr341 
are mainly involved in hydrophobic contacts between these compounds and the enzyme. 
Pi-sigma interaction has been found between the compounds V1 (C18) and V21 (C7) 
with the residue Trp286. Besides pi-sigma interaction, pi-pi interaction was observed 
between the compound V18 with the residues Trp286 and compound V21 with the 
residues Trp286 and Tyr72.  
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5.3.2 Amyloid beta (Aβ) peptide aggregation assay 
The compounds that showed the greatest AChE inhibitory activity (V1, V2, 
V12, V18 and V21) were tested for their ability to inhibit Aβ peptide aggregation 
employing the thioflavin T fluorescence method and using propidium, a known 
inhibitor acting at the AChE peripheral site, as a standard compound.  
 
Table 5.3: Inhibition of self-induced Aβ peptide aggregation by selected compounds. 
 
 
Aβ peptide 
aggregation 
No. Zinc ID 
% Inhibition at 
10 µM a 
V1 ZINC04293012 60 
V2 ZINC00033528 22 
V12 ZINC04293010 51 
V18 ZINC01668161 10 
V21 ZINC02190312 8 
 Propidium* 83b 
 
a Values are expressed as mean of triplicate, b Tested at 8.2 µM, * Standard inhibitor 
  
The results summarized in Table 5.3 indicate that compounds V1 and V12 
inhibited Aβ peptide aggregation at 10 µM at a level which is comparable to that of the 
standard inhibitor propidium, which caused 83 % inhibition at final concentration of 8.2 
µM. 
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5.4 CONCLUSION 
Compounds identified in the virtual screening study were tested using the 
Ellman assay to evaluate their inhibitory activity against AChE. Four of the compounds 
(V1, V12, V18 and V21) were found to be potent inhibitors of AChE, with IC50 values 
in the range 1–15 µM.  
 
Inhibition studies on self-induced Aβ peptide aggregation showed that two 
compounds (V1 and V12) can exert more than 50 % inhibition on Aβ aggregation at a 
final concentration of 10 µM.  Since these compounds are PAS binding ligands of 
AChE, they have the potential to interact with the Aβ binding site thus inhibiting 
AChE-induced beta amyloid aggregation. 
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CHAPTER 6: EVALUATION OF 2´-HYDROXY-AND 2´-METHOXY 
CHALCONES AS INHIBITORS OF ACETYLCHOLINESTERASE ACTIVITY 
AND AMYLOID BETA PEPTIDE AGGREGATION  
  
6.1 INTRODUCTION 
  Chalcones, or 1,3-diaryl-2-propen-1-ones, are compounds belonging to the 
flavonoid family and posses important biological activities such as anthelmintic, 
antibacterial, amoebicidal, antiviral, insectidal, antiprotozoal, anticancer, cytotoxic, 
antiulcer and immunosuppressive activities (Dimmock et al., 1999). It also has been 
reported that chalcones have the potential to inhibit acetylcholinesterase (AChE) (Amor 
et al., 2005; Aurangzen Hasan, 2005). Even though chalcones have been tested for 
anticholinesterase activity, there are no reports of chalcones that bind specifically to the 
peripheral anionic site (PAS) of AChE. 
 
  In this study, we describe the evaluation of the anticholinesterase activity of a 
series of chalcones using the Ellman colorimetric assay. Since three-dimensional 
structure information of the complex structure of ligands and AChE is available in the 
Protein Data Bank (PDB), a docking model built with AutoDock 4.0 was generated for 
active chalcones and the protein-ligand binding interactions were studied in order to 
identify whether those chalcone that inhibited AChE could bind to the PAS of AChE. 
The compounds that showed the best AChE inhibitory potency were also tested to 
assess their ability to inhibit amyloid beta (Aβ) peptide aggregation employing the 
thioflavin T fluorescence method. 
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6.2 MATERIALS AND METHODS 
The compounds were synthesized by Dr. Chee from Department of Chemistry, 
University of Malaya (Chee, 2011). 
 
6.2.1 Anticholinesterase assay  
Refer to section 4.2  
 
6.2.2 Docking studies 
6.2.2.1 Preparation of protein file 
 The AChE crystal structure, Human AChE (hAChE) in complex with fasciculin 
II (2.76 Ǻ) (PDB ID: 1b41) was extracted from the PDB as a pdb file. The heteroatoms 
and water molecules were removed using Discovery Studio Visualizer 3.1 (Accelrys, 
Inc, Sandiego, CA, USA). Hydrogens were added and double coordinates were 
corrected using Hyper chem Pro 6.0 software. Then, again hydrogens were added, non-
polar hydrogens were merged and the missing atoms were repaired using AutoDock 
Tools 1.5.2 software. Finally, the kollman charges were added and AutoDock 4 type 
atoms were assigned to the protein. 
 
6.2.2.2 Preparation of ligand file 
 3-Dimensional structural models of compounds C12, C14, C15 and C18 were 
built using Chem Bio-3D software and saved in MOL2 format. These compounds were 
prepared in protonated form where appropriate for physiological pH. Then, they were 
minimized through the Hyper chem Pro 6.0 software (Geometry optimization – MM+) 
to the lowest energy.  
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6.2.2.3 Molecular docking 
Compounds C12, C14, C15 and C18 were docked to the hAChE structure in 
complex with fasciculin II (2.76 Ǻ) (PDB ID: 1b41), using AutoDock 4.0. Docking was 
carried out using the hybrid Lamarckian Genetic Algorithm, with an initial population 
of 150 randomly placed individuals and a maximum number of 2500000 energy 
evaluations. Spacing was set to 0.375 and rmstol value was set to 2.0. Grid box was 
created by adjusting the defaults value to cover the entire protein. Ligand - protein 
interactions were analyzed using Viewer Lite, Discovery Studio Visualizer 3.1 and Lig 
plot 4.4.2 softwares. 
 
6.2.3 Aβ peptide aggregation assay  
Refer to section 4.3 
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6.3 RESULTS AND DISCUSSION 
6.3.1 Anticholinesterase activity  
The anticholinesterase activity of the prepared chalcones was determined at 10 
µM using the method of Ellman et al. (1961) and the results are shown in Table 6.1. 
The IC50 values of the active compounds were also determined and were found to be 
40–350 µM. 
 
Compounds C4, C8, C11, C12, C14, C15, C17 and C18 have a hydroxyl group 
on ring A and showed cholinesterase inhibitory activity in the micro molar range. The 
present study indicated that a hydroxyl group on ring A ortho to the side chain is 
essential for inhibitory activity of chalcones towards AChE. This is supported by the 
earlier work of Aurangzen Hasan (2005) where it has been proven that hydroxyl group 
on ring A ortho to the side chain is responsible for AChE inhibitory activity.  
 
Compounds C12, C14, C18 and C15 with halogen substituents (Cl/Br) on ring 
B showed good activity compared to other chalcones. This indicates that halogen 
groups on ring B may be important for cholinesterase inhibitory activity. In detail, 
compound C18 with bromo substitution at position C-4 showed better inhibitory 
activity compared to compounds C14 and C15. This shows that a halogen group 
specifically on C-4 on ring B seems to be an important requirement for optimal AChE 
inhibition of compounds bearing methoxyl substituents at positions C-4´ and C-6´. 
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Table 6.1: Structural data and  anticholinesterase activity of chalcones 1–27. 
1'
2'
3'
4'
5'
6 '
1
2
3
4
5
6
A B
O  
Cpd. 2  ´ 3  ´ 4  ´ 5  ´ 6  ´ 2 3 4 5 6 
% 
Inhibition  
at 
 10 µM a 
IC50   
±  
SEM 
(µM) 
C1 OH H H H H H H H H H 11  
C2 OH H H H H H H CH3 H H -  
C3 OH H H H H H H OCH3 H H 6  
C4 OH H H H H H H N(CH3)2 H H 28 266 ± 48 
C5 OH H H H H H H Br H H -  
C6 OH H H H H H H Cl H H -  
C7 OH H H H H H O-CH2-O H H 1  
C8 OH H H H H H OCH3 OH H H 22 209 ± 102 
C9 OH H H H H H OCH3 OCH3 OCH3 H -  
C10 OH H H H H H OCH3 OCH3 H H 10  
C11 OH H H H H H OH OH H H 29 177 ± 21 
C12 OH H H H H Br H H H H 38 55 ± 12 
C13 OH H H H H OH Cl H Cl H -  
C14 OH H OCH3 H OCH3 OH Cl H Cl H 51 73 ± 22 
C15 OH H OCH3 H OCH3 Br H H H H 23 85 ± 16 
C16 OH H OCH3 H OCH3 H O-CH2-O H H 5  
C17 OH H OCH3 H OCH3 H H CH3 H H 23 354 ± 133 
C18 OH H OCH3 H OCH3 H H Br H H 30 41 ± 13 
C19 OH H OCH3 H OCH3 H OCH3 OCH3 H H 8  
C20 OH H OCH3 H OCH3 H OCH3 OH H H 10  
C21 OH H OCH3 H OCH3 H H OCH3 H H 7  
C22 OH H OCH3 H OCH3 H H N(CH3)2 H H 5  
C23 OH H OCH3 OCH3 H H OCH3 OCH3 H H 10  
C24 OCH3 H OCH3 OCH3 H H OCH3 OCH3 H H 1  
C25 OCH3 H OCH3 H OCH3 H OH OH H H 6  
C26 OCH3 H OCH3 H OCH3 H OCH3 OCH3 H H 3  
C27 OCH3 H OCH3 H OCH3 H H H H H 2  
 
a Values are expressed as mean of triplicate, - = No activity observed at 10 µM 
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6.3.2 Docking studies 
To investigate possible ligand - AChE interactions, docking studies were 
performed to generate binding model for the chalcones C4, C8, C11, C12, C14, C15, 
C17 and C18 towards hAChE.  
 
Table 6.2: Correlation between the experiment and computational Ki values for the 
anticholinesterase activity of chalcones 1–27. 
 
Compound Experimental 
data 
Computed data 
 Ki ± SEM 
(µM) 
Ki (µM) Binding 
site 
C4 133 ± 24 60.64 PAS 
C8 105 ± 51 104.15 PAS 
C11 89 ± 11 45.21 PAS & CAS 
C12 28 ± 6 22.56 PAS 
C14 37 ± 11 102.29 PAS 
C15 43 ± 8 48.79 PAS 
C17 177 ± 67 180.72 PAS 
C18 21 ± 7 56.78 PAS 
Tacrine* 0.13 ± 0.01 20.51 CAS 
Propidium* 5.7 ± 0.7 95.81 PAS 
 
PAS = Peripeheral anionic site, CAS = Catalytic site, *Standard inhibitor of AChE 
 
The hydroxyl group on ring A ortho to the side chain of compound C18 forms a 
hydrogen bond to Ser293 (2.78 Aº) and Ser293 (2.73 Aº). This compound is a PAS 
binding ligand as it interacts mainly with the residue Trp286 at the PAS of the enzyme 
(Fig. 6.5 a & b). Residues such as His287, Gln291, Val294, Phe295, Arg296, Phe297 
and Phe338 are contributing for van der waals interaction while pi-sigma (1.874 Aº) 
interaction was formed between the ligand and the residue Leu289. 
  
It has been observed that hydroxyl group of compound C12 forms a hydrogen 
bond to the residue Tyr72 (1.981 Aº) (Figure 6.2a). It was also found to have pi-pi 
interaction with the residue Trp286 and hydrophobic interactions with several other 
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residues such as Tyr72, Tyr124, Trp286, Val 294, Phe295, Phe297, Tyr337, Phe338 and 
Tyr341 at PAS region of AChE (Figure 6.2b). Meanwhile, residues such as Tyr124, 
Phe297, Tyr337, Phe338 and Tyr341 are also involved in Van der waals interaction.  
 
The hydroxyl group on ring A ortho to the side chain of compound  C14 forms a 
hydrogen bond to Asp74 (3.10 Aº). Meanwhile, another hydrogen bond was observed 
between the hydroxyl group on ring B ortho to the side chain of compound C14 with 
Tyr124 (3.05 Aº). There was a hydrophobic contact between the ligand and the residues 
Leu76, Tyr124, Trp286 and Tyr341 indicating that this ligand is a PAS binder (Figure 
6.3b). Docking investigation has also found that the residues Phe297, Phe338 and 
Tyr341 are involved in Van der waals interaction and the residue Trp286 contributes to 
pi-sigma interaction (Figure 6.3a). 
 
As shown in Figure 6.4b, the hydroxyl group on ring A ortho to the side chain 
of compound C15 forms two hydrogen bonds. One is with Tyr72 (2.77 Å) and another 
is with Asp74 (2.91 Å). This compound is a PAS binding ligand since there is a 
hydrophobic contact between the ligand and the residues Leu76, Trp286, Phe297, 
Tyr337, Phe338 and Tyr341 which involves the PAS region of AChE. Further 
investigation has also shown that residues Tyr124, Phe297, Tyr337, Tyr338 and Tyr341 
are involved in van der waals interaction and Trp286 favorable for pi-pi interaction. 
Docking studies on compounds C4, C8, C11 and C17 indicated that compound C11 is 
both PAS and CAS binding ligand whereas compounds C4, C8 and C17 are PAS 
binders.  
 
A correlation study was carried out to investigate the relationship between the 
experimental and docking study (Figure 6.1). The study has shown a correlation (R2 = 
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0.33) for the present series of compounds. The docking analysis has roughly predicted 
the binding locations for compounds which have been tested in this study. The r2 value 
can be improved further by increasing the number of compounds being tested in this 
study. 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Correlation plot of experimental pKi (anticholinesterase activity) vs 
computed pKi (docking studies). 
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(a) 
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Figure 6.2: a) 3D representation of hAChE complex with compound C12 (green) at the 
PAS region of the AChE. b) Ligplot analysis to show the molecular interactions 
(hydrophobic and hydrogen bonds) between the ligand and the protein. 
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(a)  
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
 
 
Figure 6.3: a) 3D representation of hAChE complex with compound C14 (green) at the 
PAS region of the AChE. b) Ligplot analysis to show the molecular interactions 
(hydrophobic and hydrogen bonds) between the ligand and the protein. 
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(b)  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: a) 3D representation of hAChE complex with compound C15 (green) at the 
PAS region of the AChE. b) Ligplot analysis to show the molecular interaction 
(hydrophobic and hydrogen bonds) between the ligand and the protein. 
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Figure 6.5: a) 3D representation of hAChE complex with compound C18 (green) at the 
PAS region of the AChE. b) Ligplot analysis to show the molecular interactions 
(hydrophobic and hydrogen bonds) between the ligand and the protein. 
 
 
 
 92 
6.3.3 Aβ PEPTIDE AGGREGATION ASSAY 
The compounds that showed the greatest AChE inhibitory activity [compounds 
C4, C8, C11, C12, C15, C17 and C18 (compound C14 wasn’t tested due to insufficient 
amount)] were selected to assess their ability to inhibit Aβ peptide aggregation 
employing the thioflavin T fluorescence method. Propidium, a known inhibitor acting at 
the AChE peripheral site was used as a standard compound. The results summarized in 
Table 6.3 indicated that compounds C4, C11, C15 and C18 inhibited the Aβ peptide 
aggregation at 10 µM at a level which is comparable to as potent as propidium, which 
caused 80 % inhibition at a final concentration of 8.2 µM. 
 
Table 6.3: Inhibition of self-induced Aβ peptide aggregation by compounds with the 
greatest AChE inhibitory activity. 
 
Aβ peptide 
aggregation  
Compound 
% Inhibition at  
10 µM a    
C4 52 
C8 5  
C11 42 
C12 17 
C14 NE 
C15 45  
C17 3  
C18 79 
Propidium* 80b  
 
a Values are expressed as mean of triplicate, * Standard inhibitor, b Tested at 8.2 µM, 
NE = not estimated 
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6.4 CONCLUSION 
  In conclusion, the overall docking analysis for the 8 compounds (C4, C8, C11, 
C12, C14, C15, C17 and C18) which were found to inhibit AChE showed that these 
compounds bind at the PAS region of AChE except for compound C11 which is both a 
PAS and CAS binding ligand. Molecular docking studies for compounds C14, C15 and 
C18 have further demonstrated the importance of hydroxyl group on ring A ortho to the 
side chain which is mainly involved in forming a hydrogen bond with protein residues. 
The most active compounds C12, C14, C15 and C18 were found to form hydrogen 
bonds with Tyr72, Asp74, Tyr124, Ser293, Phe295 and Arg296. Leu76, Trp286, 
Phe297, Tyr337, Phe338 and Tyr341 are seem to be an important residues as they are 
interact with these ligands by hydrophobic interactions. Furthermore, inhibition studies 
on self-induced Aβ aggregation has found that compound C18 can exert an 
antiaggregation effect. In the present study, the combination of experimental and 
computational approach has successfully shown that some chalcones have the potential 
to inhibit amyloid beta aggregation thus preventing or delaying the degeneration of 
cholinergic neurons. 
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CHAPTER 7: GENERAL CONCLUSION AND FUTURE PERSPECTIVES 
In the current study, a number of crystal structures of acetylcholinesterase 
(AChE) were extracted from the Protein Data Bank (PDB) and docked with known 
ligands to find a suitable structure for virtual screening. The blind docking results using 
a structure obtained from human acetylcholinesterase (hAChE) in complex with 
fasciculin II (PDB ID: 1b41) showed that most of the peripheral anionic site (PAS) 
binding ligands bound near the aromatic residue Trp286. This structure was found to be 
the most suitable for identifying PAS ligands and therefore was chosen for virtual 
screening.  
 
The selected protein structure was then docked with a library of 830 
commercially available ligands using computational procedures in order to identify 
potential anticholinesterase compounds and the lowest binding energy was exhibited by 
compound V1. About 21 compounds with a lowest binding energy range from -8.72 
kcal/mol to -5.60 kcal/mol were selected for testing. 
 
An assay to measure AChE inhibitory activity was optimised and used to 
evaluate the compounds identified from the virtual screening. Several compounds 
showed good activity with IC50 values in the range 1–15 µM. The most potent inhibitor, 
compound V18, inhibited AChE with IC50 of 1.54 µM. Molecular modeling studies 
showed this compound bound to the catalytic site (CAS) and PAS of the enzyme near 
the aromatic residues Trp86 and Trp286, respectively.  
 
A self-induced amyloid beta (Aβ) peptide aggregation assay was optimised and 
used to evaluate the compounds with good AChE inhibitory activity. They were found 
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to inhibit Aβ peptide aggregation at 10 µM in the range 8 % to 60 % with compound V1 
showing the highest activity. 
The anticholinesterase activity, and molecular interactions of a series of 
chalcones were also investigated in this study. Docking studies has indicated that the 
active compounds C4, C8, C12, C14, C15, C17 and C18 are PAS binders whereas 
compound C11 is both a PAS and CAS binding ligand. Chalcones with greatest AChE 
inhibitory potency (C4, C8, C11, C12, C14, C15, C17 and C18) were selected to assess 
their ability to inhibit Aβ peptide aggregation. The results indicated that these 
compounds gave inhibition at 10 µM in a range varying from 5 % to 79 %. Compound 
C18 was found to be as potent as propidium, which caused 80 % inhibition at a final 
concentration of 8.2 µM. 
 
In summary, we have identified some promising PAS-binding anticholinesterase 
compounds which show high inhibitory activity towards AChE and self-induced Aβ 
aggregation. Since other PAS-binding ligands such as propidium, and decamethonium 
have been found to inhibit AChE-induced Aβ aggregation, it can be hypothesized that 
the active compounds from this study might also have a significant effect in modulating 
this pathway. Therefore, further studies are required to investigate the effect of these 
compounds towards AChE-induced Aβ peptide aggregation and determine the 
inhibition mode of these compounds.  
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